Skip over navigation
Printable version [PDF]
PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D 519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G 69/00; macromolecular products derived from proteins C08H 1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N 15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N 33/00)
Relationship between large subject matter areas

An amino acid per se is classified in C07D while peptides (starting from dipeptides) are classified in C07K.

Subclass C07K is a function oriented entry for the compounds themselves and does not cover the application or use of the compounds under the subclass definition. For classifying such information other entries in EC exist, for example: preservation of bodies of humans or animals or plants or parts thereof; Biocides, e.g. as disinfectants, as pesticides, as herbicides; pest repellants or attractants; plant growth regulators are classified in A01N.

Preparations for medical, dental, or toilet purposes are classified in A61K.

Amino acids or derivatives thereof are classified in C07C or C07D.

Multiple classification: Biocidal, pest attractant, or plant growth regulatory activity of chemical compounds or preparations is classified in A01P.

Uses of cosmetics or similar toilet preparations are further classified in A61Q.

References relevant to classification in this subclass
This subclass does not cover:

Peptides containing beta-lactam rings

Cyclic dipeptides not having in their molecule any other peptide link than those which form their ring; e.g. piperazine-2,5-diones

Ergot alkaloids of the cyclic peptide type

Enzymes

Genetic engineering processes for obtaining peptides

Peptides and proteins obtained by fermentation or enzyme-using processes are classified in

Electrolytic production of organic compounds

Informative references
Attention is drawn to the following places, which may be of interest for search:

Peptides in foodstuffs

Peptides in animal feed

Macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific, but for a random sequence of the amino acid units, homopolyamides and block copolyamids derived from amino acids

Macromolecular products derived from proteins

Preparation of glue or gelatine

Micro-organisms

Compositions for measuring or testing processes involving enzymes

Investigation or analysis of biological materials

Analytical devices

Special rules of classification within this group

In this subclass, in the absence of an indication to the contrary, a compound is classified in the last appropriate place.

Fragments of peptides or peptides modified by removal or addition of amino acids, by substitution of amino acids by others, or by combination of these modifications are classified as the parent peptides (however only if they have the same activity). Peptide fragments having up to four amino acids are classified in group C07K 5/00.

Peptides prepared by chemical processes or having an amino acid sequence derived from naturally occurring peptides are classified with the naturally occurring peptide.

Peptides prepared by recombinant DNA technology are not classified according to the host, but according to the original peptide expressed, e.g. HIV peptide expressed in E. coli is classified with HIV peptides.

When classifying in this subclass, classification is also made in group B01D 15/08 insofar as subject matter of general interest relating to chromatography is concerned.

Specific peptides mentioned in the claims and/or examples are classified.

The technical field of C07K 1/00 - C07K 5/126 is subdivided into three major blocks:

General methods for preparation of peptides/proteins

General methods for extraction, separation and purification of proteins and peptides

Peptide compounds per se containing up to four amino acids

Should not be used anymore for classification

Glossary of terms
In this subclass, the following terms (or expressions) are used with the meaning indicated:

Amino acid

compounds in which at least one amino acid group and at least one carboxylic group are bound to the same carbon skeleton and the nitrogen atom of the amino group may be part of a ring

Normal peptide link

a link between an alpha-amino group of an amino acid and the carboxylic group in position 1 of another alpha-amino acid

Abnormal peptide link

a link where at least one of the linked amino acids is not an alpha- amino acid or a link formed by at least one carboxyl or amino group being a part of the side chain of an alpha-amino acid. Peptide compounds containing at least two amino acid units, which are bound through at least one normal peptide link, including oligopeptides, polypeptides and proteins.

Linear peptides

may comprise rings formed through S-S bridges, or through an hydroxy or a mercapto group of an hydroxy- or a mercapto-amino acid and the carboxyl group of another amino acid (e.g. peptide lactones) but do not comprise rings which are formed only through peptide links.

Cyclic peptides

comprising at least one ring formed only through peptide links; the cyclisation may occur only through normal peptide links or through abnormal peptide links, e.g. through the 4-amino group of 2,4-diamino-butanoic acid. Thus, cyclic compounds in which at least one link in the ring is a non-peptide link are considered as' linear peptides'.

Depsipeptides

compounds containing a sequence of at least two alpha-amino acids and at least one alpha-hydroxy carboxylic acid, which are bound through at least one normal peptide link and ester link, derived from the hydroxy carboxylic acids

Linear depsipeptides

may comprise rings formed through S-S bridges, or through an hydroxy or a mercapto group of an hydroxy- or mercapto-amino and and the carboxyl group of another amino- or hydroxy-acid but do not comprise rings formed only through peptide or ester links derived from hydroxy carboxylic acids, e.g. Gly-Ala-Gly-OCH2CO2H and Gly-OCH2CO-Ala-Gly are considered as “linear depsipeptides, but HOCH2CO-Gly-Ala-Gly does not contain an ester link, and is thus a derivative of Gly-Ala-Gly which is covered by C07K 5/08

Cyclic depsipeptides

are peptides containing at least one ring formed only through peptide or ester link - derived from hydroxy carboxylic acids -, e.g. Gly-Ala-Gly-OCH2CO

Hybrid peptides

are peptides produced through fusion or covalent binding of two or more heterologous peptides.

General methods for the preparation of peptides {, i.e. processes for the organic chemical preparation of peptides or proteins of any length}
Definition statement
This group covers:

General processes for the organic chemical preparation of peptides (exception see C07K 1/113).

Peptides e.g. oligopeptides, polypeptides, proteins Immunoglobulins.

Carrier-bound or immobilised peptides and preparation thereof.

Hybridpeptides.

"Peptides" in this main group includes oligopeptides, polypeptides, proteins and chemically modified forms thereof, i.e. the definition of peptide is independent of the length in amino acids.

Peptides comprise at least two alpha-amino acids joined by a single peptide bond.

{by transforming the C-terminal amino acid to amides}
Definition statement
This subgroup covers:

Reactions concerning transformation of the C-terminal amino acid to amides.

{of peptides containing derivatised side chain amino acids}
Definition statement
This subgroup covers:

Preparation of peptides containing derivatised side chain amino acids such as e.g. pseudo proline, non natural amino acids, and chemically phosphorylated amino acids.

in solution {(C07K 1/003, C07K 1/006 take precedence)}
Definition statement
This subgroup covers:

General methods for solution phase peptide synthesis.

Special rules of classification within this group

Main group concerns methods for solution phase peptide synthesis applicable to peptides in general. Methods directed to solution phase peptide synthesis of a single peptide or protein needs to be classified in the pertinent group for that specific peptide or protein.

C07K 1/003, C07K 1/006 take precedence.

The class C07K 1/023 should be given if the focus of solution phase peptide synthesis is on inhibition of racemate formation.

Solution-phase peptide synthesis may comprise enzymes as catalysts.

Glossary of terms
In this subgroup, the following terms (or expressions) are used with the meaning indicated:

Peptides

oligopeptides, polypeptides, proteins and chemically modified forms thereof.

on carriers {(C07K 1/003, C07K 1/006 take precedence)}
Special rules of classification within this group

C07K 1/003, C07K 1/006 take precedence.

Specific aspects of synthesis on carriers, such as deprotection, new solvents, should be classified in the respective subclasses.

{using devices to improve synthesis, e.g. reactors, special vessels}
References relevant to classification in this group
This subgroup does not cover:

Apparatus per se

{Simultaneous synthesis of different peptide species; Peptide libraries}
Definition statement
This subgroup covers:

Organic chemical methods for simultaneous multiple peptide synthesis and organic chemical synthesis of peptide libraries.

References relevant to classification in this group
This subgroup does not cover:

Combinatorial chemical libraries

Carrier-bound immobilised peptides are classified in, if the invention relies in the carrier and/or the anchoring linkages

Libraries per se, arrays, containing peptides or polypeptides, or derivatives thereof

Peptide libraries produced by recombinant DNA technology

using protecting groups or activating agents {(C07K 1/003, C07K 1/006 take precedence)}
Definition statement
This subgroup covers:

General methods for the preparation of peptides using protecting groups or activating agents.

Special rules of classification within this group

Multiple classification if a plurality of protecting groups is claimed.

Please avoid, where possible, classification in the head group C07K/06,

C07K 1/003, C07K 1/006 take precedence.

using activating agents {(C07K 1/003, C07K 1/006 take precedence)}
Special rules of classification within this group

C07K 1/003, C07K 1/006 take precedence.

For coupling of peptides the carboxyl group is activated. Thus activating agent are generally agents which activate the carboxyl group by forming an activated ester, such as DCC, DIC, BOP, PyBOP, HBTU, TBTU.

Activating agents are to be distiguished from coupling agents which do not form an activated ester but are oxidized during the peptide bond formation.

using coupling agents {(C07K 1/006 takes precedence)}
Definition statement
This subgroup covers:

General methods for the preparation of peptides using coupling agents.

Special rules of classification within this group

C07K 1/006 takes precedence.

For coupling of peptides the carboxyl group is activated. Thus activating agent are generally agents which activate the carboxyl group by forming an activated ester, such as DCC, DIC, BOP, PyBOP, HBTU, TBTU.

Activating agents are to be distinguished from coupling agents which do not form an activated ester but are oxidized during the peptide bond formation.

{by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids}
Definition statement
This subgroup covers:

General methods for the preparation of peptides by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids.

References relevant to classification in this group
This subgroup does not cover:

Combinatorial chemical libraries

Carrier-bound immobilised peptides

Libraries per se, arrays, containing peptides or polypeptides, or derivatives thereof

Peptide libraries produced by recombinant DNA technology

Special rules of classification within this group

Peptide arrays or libraries are NOT classified in C07K 1/1077.

without change of the primary structure
Definition statement
This subgroup covers:

General methods for the preparation of peptides without change in the primary structure, e.g. by reversible modification of the secondary, tertiary or quaternary structure.

Special rules of classification within this group

In this subclass as an exception to the general rule that methods have to be applicable to peptides in general, exceptionally also methods relating to a single peptide or protein are classified.

by hydrolysis {, i.e. solvolysis in general}
References relevant to classification in this group
This subgroup does not cover:

Peptides obtained by fermentation

Special rules of classification within this group

Documents directed to peptide or protein sequencing have also been classified in the past in G01N 33/68.

General methods for the preparation of peptides by hydrolysis covers peptide or protein sequencing techniques (sequential hydrolysis of peptides or protein).

Labelling of peptides
Definition statement
This subgroup covers:

General chemical methods for the preparation of peptides by labelling e.g. with dyes, radioactive or fluorescents labels.

Subgroup concerns methods which are applicable to peptides of any length in general! Methods directed to the preparation of a specific peptide or protein needs to be classified in the pertinent group for that specific peptide or protein.

Relationship between large subject matter areas

Isotope labelled peptides per se are classified in C07B 59/008.

Informative references
Attention is drawn to the following places, which may be of interest for search:

Peptides forming the non active part of a conjugate for use as a therapeutic agent

Peptides forming the non active part of a conjugate for use as an in vivo imaging agent by fluorescense

Peptides possibly part of a conjugate, for use as an in vivo imaging agent by X-ray imaging

Peptides possibly part of a conjugate for use as an in vivo imaging agent by magnetic resonance imaging

Peptides possibly part of a conjugate for use as an in vivo imaging agent by ultrasound imaging

Preparations containing radioactive peptides for use in therapy and in vivo imaging are classified in Preparations containing radioactive peptides for use in therapy and in vivo imaging

Peptide conjugates where the innovation is on the conjugated part

Extraction; Separation; Purification
References relevant to classification in this group
This subgroup does not cover:

Methods directed to purification of antibodies from serum, plasma, or other body fluids are classified in C07K 16/065. However, if the focus is on technical aspect of purification as such, the method should also be classified in C07K 1/14 - C07K 1/36. Purification of antibodies from a solution, cell culture, and the like, is classified in C07K 1/14 - C07K 1/36.

Informative references
Attention is drawn to the following places, which may be of interest for search:

Antibodies isolated from milk are also classified in

Special rules of classification within this group

Please avoid where you can classifying in the head group.

by chromatography
Definition statement
This subgroup covers:

Only chromatographic methods applicable for peptides or proteins as such are classified here.

Relationship between large subject matter areas

Chromatographic materials as such are classified in B01J 20/281 - B01J 20/292, B01J 39/26 (cation exchangers), B01J 41/20 (anion exchangers).

B01D 15/08 relates to processes and apparatus for chromatography in general.

{by crystallization}
References relevant to classification in this group
This subgroup does not cover:

Methods with emphasis on growing large single crystals of protein from solutions

For the crystal

by a combination of two or more processes of different types
Definition statement
This subgroup covers:

A combination of two or more processes of different types means that at least two steps are innovative.

Peptides of undefined number of amino acids; Derivatives thereof
Special rules of classification within this group

Please avoid classifying in this group. Consider classification only in exceptional cases where the protein is not identifiable by the sequence or otherwise.

Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
Special rules of classification within this group

Please avoid classifying in this group. Consider classification only in exceptional cases where the protein is not identifiable by the sequence or otherwise.

Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
Definition statement
This group covers:

Peptides containing up to four amino acids in a fully defined sequence and derivatives thereof. Peptides containing up to four amino acids in a fully defined sequence and containing saccharide radicals are not covered by this group (see references relevant to classification below).

References relevant to classification in this group
This group does not cover:

Medical uses of novel short peptides

Dipeptides

Tripeptides

Tetrapeptides

Depsipeptides

Cosmetic preparations containing peptides

Peptides containing up to four amino acids in a fully defined sequence and containing saccharide radicals

Informative references
Attention is drawn to the following places, which may be of interest for search:

Peptides with up to 4 amino acids labelled with isotopes are also classified in

Depsipeptides with up to 4 amino acids are also classified in

Peptides with up to four amino acids prepared by fermentation (not recombinantly expressed) are also classified in

Chemically synthesized hybrid peptides with up to 4 amino acids are also classified in

Fusion polypeptides

Peptides up to 4 amino acids in length forming the non active part of a conjugate, for use as a therapeutic agent, are also classified in

Peptides up to 4 amino acids in length forming the active part of a conjugate to an antibody, for use as a therapeutic agent, are also classified in

Peptides up to 4 amino acids in length forming the non active part of a conjugate, for use as an in vivo imaging agent by fluorescense, are also classified in

Peptides up to 4 amino acids in length, possibly part of a conjugate, for use as an in vivo imaging agent by X-ray imaging, are also classified in

Peptides up to 4 amino acids in length, possibly part of a conjugate, for use as an in vivo imaging agent by magnetic resonance imaging, are also classified in

Peptides up to 4 amino acids in length, possibly part of a conjugate, for use as an in vivo imaging agent by ultrasound imaging, are also classified in

Preparations containing radioactive peptides for use in therapy and in vivo imaging are also classified in

Peptide conjugates where the innovation is on the conjugated part are classified in

Special rules of classification within this group

Although C07K 5/00- C07K 5/126 concern short peptides per se, there is one exception: methods for purification and preparation of aspartame are classified with aspartame in C07K 5/0613.

containing at least one abnormal peptide link
Definition statement
This subgroup covers:

Peptides per se, and derivatives thereof, having up to four amino acids in a fully defined sequence and containing at least one abnormal peptide link are classified in this subgroup only.

Special rules of classification within this group

Mainly protease inhibitors, such as statins, have been classified here.

{containing the structure -C(=O)-C-N-C(=O)-N-C-C(=O)-}
Definition statement
This subgroup covers:

Peptides, and derivatives thereof, having up to four amino acids in a fully defined sequence and containing the structure [-C(=O)-C-N-C(=O)-N-C-C(=O)-]

Special rules of classification within this group

Peptides with symmetrical structure.

containing only normal peptide links
Definition statement
This subgroup covers:

Peptides, and derivatives thereof, having up to four amino acids in a fully defined sequence and containing only normal peptide links.

Glossary of terms
In this subgroup, the following terms (or expressions) are used with the meaning indicated:

Neutral amino acids

have in their side chains the same number of amino groups and carboxylic acid groups or derivatives thereof, e.g. Gly

Basic amino acids

have in their side chains more amino groups than carboxylic acid groups or derivatives thereof, e.g. Arg, Lys

Acidic amino acids

have in their side chains more carboxylic acid groups or derivatives thereof than amino groups, e.g. Asp, Glu; Gln and Asn are also considered as acidic amino acids

Aliphatic amino acids

have only acyclic carbon atoms in their side chains, e.g. Ala

Aromatic or cycloaliphatic amino acids

have a carbocyclic in ring in their side chains, e.g. Phe

Heterocyclic amino acids

are amino acids wherein the side chain contains or is part of a heteroring, e.g. Pro, His, Trp

Side chain

the R radical in the optionally functionalised amino acid RCH(NH2)C O2H)

First amino acid

means the N-terminal amino acid of the peptide sequence

{Aspartame}
Special rules of classification within this group

Although C07K 5/00- C07K 5/126 concern short peptides per se, there is one exception: methods for purification and preparation of aspartame are classified with aspartame in C07K 5/0613.

Cyclic peptides {with only normal peptide bonds in the ring}
Definition statement
This subgroup covers:

Peptides, and derivatives thereof, having up to four amino acids in a fully defined sequence in a cyclic form and containing only normal peptide bonds.

References relevant to classification in this group
This subgroup does not cover:

Cyclic peptides containing at least one abnormal peptide link

Special rules of classification within this group

Classify here only if cyclisation occurs via normal peptide links.

Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
Definition statement
This group covers:
  • Oligomers of amino acids making up a sequence of between 5 and 20 residues in length containing at least one alpha peptide bond, which is also a normal peptide bond.
  • Genes and nucleotide sequences coding for the above peptides.
  • Crystals of the above peptides.
  • Specific methods for the preparation of the above peptides.

Peptides having 5 to 20 amino acids in a fully defined sequence and containing saccharide radicals are not covered by this group (see references relevant to classification below).

References relevant to classification in this group
This group does not cover:

Pharmaceutical/dental/cosmetic/toilet uses and compositions of peptides that were already known at the time are classified in

E.g. in one or more of the following:For dental, cosmetic and toilet indications:

For pharmaceutical and medical purposes

Fragments of proteins should be classified with the parent polypeptide

Fragments of enzymes should be classified with the parent compound

Fragments of immunoglobulins should be classified with the parent compound

Fragments of peptides included in this main group and having 4 or less amino acids

Peptides having 5 to 20 amino acids in a fully defined sequence and containing saccharide radicals

Peptides in foodstuff

A23

Investigation or analysis of peptides, including peptide sequencing, as well as diagnostic and/or analytical uses of peptides

Methods for the preparation of generic peptides (e.g. by chemical synthesis)

Methods for the preparation of generic peptides (fermentative or enzyme-based procedures)

Oligomers of amino acids with no normal peptide bond are classified with the organic compounds in the preceding

C07

Fusion peptides are additionally classified in

Documents in which the emphasis is laid on the method of preparation of fusion proteins may also be classified in

Special rules of classification within this group

In this main group, only the specific embodiments are classified. The generic definition of a group of peptides on the basis of structural variables, which may assume different values, e.g. a Markush formula, deserves no classification mark.

In this main group, in the absence of any indication to the contrary, every specific embodiment is classified in the last appropriate place (last-place rule).

As a consequence, one embodiment can only be associated with one classification mark within C07K. A document disclosing a plurality of specific embodiments may be associated with one or more classification marks.

Peptides modified by means of one or more of additions, deletions and substitutions of amino acids are classified as the parent peptide.

As a corollary, fragments of peptides are classified with the parent peptides, which contain their sequences.

The degree of structural homology is not particularly limited, as long as the origin of the fragment or the modified peptide is established on the basis of at least one function/activity in common with the parent peptide.

Fusion peptides are classified in the classes of their components, and additionally in C07K 2319/00.

Glossary of terms
In this group, the following terms (or expressions) are used with the meaning indicated:

Amino acids

Are compounds in which at least one amino group and at least one carboxyl group are bound to the same carbon skeleton and the nitrogen atom of the amino group may form part of a ring

Normal peptide link

Is one between an alpha-amino group of an amino acid and the alpha- carboxy group of another alpha-amino acid

Abnormal peptide link

Is a link where at least one of the linked amino acids is not an alpha-amino acid or a link formed by at least one carboxyl or amino group being part of the side chain of an alpha-amino acid

Peptides

Are compounds containing at least two amino acid units, which are bound through at least one normal peptide link, including oligopeptides, polypeptides and proteins

Linear peptides

Are normal or abnormal peptides which may comprise rings formed through S-S bridges, or through a hydroxy or a mercapto group of an hydroxy -or mercaptoamino acid and the carboxyl group of another amino acid, (e.g. peptide lactones) but do not comprise rings which are formed only through peptide links

Cyclic peptides

Are peptides comprising at least one ring formed only through peptide links; the cyclisation may occur only through normal peptide links or through abnormal peptide links, e.g. through the 4-amino group of 2,4-diamino-butanoic acid. Cyclic compounds in which at least one link in the ring is a non-peptide link are considered as "linear peptides"

Related peptide and peptide derivative

It is intended a peptide, which retains at least one function/activity of the parent peptide.

Defined sequence and undefined sequence

Are used here in order to characterize an intrinsic property of the peptide, and do not refer to the actual knowledge of the amino acid sequence, i.e. the adjective defined is not used here with the same meaning of determined. Peptides with a "defined sequence" have an unique amino acid sequence and are classified as such even if their amino acid sequence has not been disclosed and is not known. An "undefined sequence" means a degeneration of the sequence information, e.g. if the peptide is defined as a random sequence of various amino acids.

Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
Definition statement
This group covers:

Peptides having up to 20 amino acids containing saccharide radicals and having a fully defined sequence and derivatives thereof. They must have at least one normal peptide link. The peptides classified above are often called glycopeptides and are defined as peptides of appropriate length (see C07K 7/00) possessing one or more glycoside groups on the side chain(s) of the constituting peptides.

Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
Definition statement
This group covers:

Depsipeptides having up to 20 amino acids in a fully defined sequence. Derivatives thereof.

Glossary of terms
In this group, the following terms (or expressions) are used with the meaning indicated:

Depsipeptides

are compounds containing a sequence of at least two alpha-amino acids and at least one alpha-hydroxy carboxylic acid, which are bound through at least one normal peptide link and at least an ester link, derived from the hydroxy carboxylic acid.

Linear depsipeptides

may comprise rings formed through S-S bridges, or through an hydroxy or a mercapto group of an hydroxy-or mercapto-amino acid and the carboxyl group of another amino- of hydroxy-acid, but do not comprise rings formed only through peptide or ester links derived from alpha-hydroxy carboxylic acids; e.g. Gly-Ala-Gly-OCH2CO2H and Gly-OCH2CO-Ala-Gly are considered as "linear depsipeptides", but HOCH2CO-Gly-Ala-Gly does not contain an ester link, and is thus a derivative of Gly-Ala- Gly which is covered by C07K 5/08.

Cyclic depsipeptides

are peptides containing at least one ring formed only through peptide or ester links derived from alpha-hydroxy carboxylic acids,e.g. cyclic Gly-Ala-Gly-OCH2CO.

Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
Definition statement
This group covers:
  • Polymers of amino acids linked by peptide bonds, and compositions containing them.
  • Genes and other polynucleotides coding for peptides.
  • Non-coding nucleic acid sequences, e.g. promoters, operators, derived from genes or operons coding for peptides
  • Fragments of peptides and nucleic acids encoding peptides (fragments smaller than 21 amino acids are classified with the parent peptides; fragments of 2-4 amino acid residues are also classified in C07K 5/00
  • Methods for preparation and purification of specific peptides are classified with these peptides. General methods are classified in C07K 1/00.
  • Fusion proteins
  • Crystallized proteins
  • Hybrid peptides (classified according to their peptide component)
Relationship between large subject matter areas

Medicinal preparations containing known peptides are not classified in C07K, only in A61K.

References relevant to classification in this group
This group does not cover:

Enzymes

Immunoglobulins

Peptides having less than 21 amino acids

Carrier-bound or immobilised peptides and preparation thereof

Proteins of humans and other mammals

Examples where the subject matter of this main group is covered when specially adapted, used for a particular purpose, or incorporated in a larger system:

Medicinal preparations containing peptides

Peptides with enzymatic activity

Informative references
Attention is drawn to the following places, which may be of interest for search:

Peptides in foodstuff

A23

Compositions for measuring or testing processes involving peptides

Investigation or analysis of peptides

Special rules of classification within this group

In this subclass, in the absence of an indication to the contrary, a compound is classified in the last appropriate place.

Methods for the preparation or purification of specific peptides are classified in the group of the corresponding peptides. However, the invention may also be valid for other peptides and such documents are also classified in C07K 1/00.

Fragments of peptides modified by removal or addition of amino acids, by substitution of amino acids by others, or by combination of these modifications are classified as the parent peptides. However, fragments of peptides having four or less amino acids are also classified in group C07K 5/00.

Specific peptides prepared by chemical processes or peptides having an amino acid sequence derived from specific peptides are classified with the specific peptides.

Protease inhibitors that are fragments of proteases are classified only in C12N 9/50-C12N 9/86, not in C07K 14/81.

Peptides prepared by recombinant DNA technology are not classified according to the host, but according to the original peptide expressed, e.g. HIV peptide expressed in E. coli is classified with HIV peptides.

Fusion peptides are classified in the classes of their components, the document has further to be given a class for fusion proteins: C07K 2319/00

Documents in which emphasis is given on the method for the preparation of fusion proteins are classified in C12N 15/62.

Hybrid peptides are classified according to their peptide component.

Glossary of terms
In this group, the following terms (or expressions) are used with the meaning indicated:

Amino acid

compounds in which at least one amine and at least one carboxylic group are bound to the same carbon skeleton and the nitrogen atom of the amino group may form a ring

Peptide bond

a link between an alpha-amino group of an amino acid and the carboxylic group – in position 1 – of another alpha-amino acid

Immunoglobulin

protein produced by B cells, made up of two identical heavy and two identical light chains, held together by interchain disulfide bonds

Hybrid peptide

peptide comprising components of heterologous molecules

Fusion peptide

peptide consisting of (parts of) different proteins covalently linked to each other by a peptide bond

Signal sequence

a 3-60 amino acids stretch that directs the transport of the protein to which it is attached

{by chemical synthesis}
Definition statement
This subgroup covers:

Preparation of proteins and peptides having more than 20 amino acids, and derivatives thereof, by chemical synthesis.

{Peptide-nucleic acids (PNAs)}
Definition statement
This subgroup covers:

Chemical synthesis of peptide-nucleic acids in which the peptide contains more than 20 amino acids.

from viruses
Definition statement
This subgroup covers:

New viral proteins or individual genes encoding said proteins, as well as new structural or functional aspects of known viral proteins or genes. Also fragments of said proteins or genes are covered.

Special rules of classification within this group

The subdivision corresponding to IPC C07K 14/01 until C07K 14/19 is no longer used, since the taxonomic division in this part of the IPC is incomplete and inconsistent with other parts of the classification relating to viruses.

The viral proteins, genes and fragments as indicated above are to be classified using the codes in the C12N 2710/00-C12N 2795/00 ranges combining taxonomic information with further aspects, whereby the specific ending 22 relates to aspects of individual viral proteins and their corresponding genes.

Only if the main invention resides in the viral protein, individual gene or fragment thereof, C07K 14/005 is to be given. No other EC class should be assigned.

from animals; from humans
Definition statement
This subgroup covers:
  • Polymers of amino acids linked by peptide bonds, and compositions containing them.
  • Genes and other polynucleotides coding for peptides.
  • Non-coding nucleic acid sequences, e.g. promoters, operators, derived from genes or operons coding for peptides
  • Fragments of peptides and nucleic acids encoding peptides (fragments smaller than 21 amino acids are classified with the parent peptides; fragments of 2-4 amino acid residues are also classified in C07K 5/00
  • Methods for preparation and purification of specific peptides are classified with these peptides. General methods are classified in C07K 1/00.
  • Fusion proteins
  • Crystallized proteins
  • Hybrid peptides (classified according to their peptide component)
Relationship between large subject matter areas

Medicinal preparations containing known peptides are not classified in C07K, only in A61K.

References relevant to classification in this group
This subgroup does not cover:

Enzymes

Immunoglobulins

Peptides having less than 21 amino acids

Carrier-bound or immobilised peptides and preparation thereof

Proteins of humans and other mammals

Examples where the subject matter of this main group is covered when specially adapted, used for a particular purpose, or incorporated in a larger system:

Medicinal preparations containing peptides

Peptides with enzymatic activity

Informative references
Attention is drawn to the following places, which may be of interest for search:

Peptides in foodstuff

A23

Compositions for measuring or testing processes involving peptides

Investigation or analysis of peptides

Special rules of classification within this group

In this subclass, in the absence of an indication to the contrary, a compound is classified in the last appropriate place.

Methods for the preparation or purification of specific peptides are classified in the group of the corresponding peptides. However, the invention may also be valid for other peptides and such documents are also classified in C07K 1/00.

Fragments of peptides modified by removal or addition of amino acids, by substitution of amino acids by others, or by combination of these modifications are classified as the parent peptides. However, fragments of peptides having four or less amino acids are also classified in group C07K 5/00.

Specific peptides prepared by chemical processes or peptides having an amino acid sequence derived from specific peptides are classified with the specific peptides.

Protease inhibitors that are fragments of proteases are classified only in C12N 9/50-C12N 9/86, not in C07K 14/81.

Peptides prepared by recombinant DNA technology are not classified according to the host, but according to the original peptide expressed, e.g. HIV peptide expressed in E. coli is classified with HIV peptides.

Fusion peptides are classified in the classes of their components, the document has further to be given a class for fusion proteins: C07K 2319/00

Documents in which emphasis is given on the method for the preparation of fusion proteins are classified in C12N 15/62.

Hybrid peptides are classified according to their peptide component.

Glossary of terms
In this subgroup, the following terms (or expressions) are used with the meaning indicated:

Amino acid

compounds in which at least one amine and at least one carboxylic group are bound to the same carbon skeleton and the nitrogen atom of the amino group may form a ring

Peptide bond

a link between an alpha-amino group of an amino acid and the carboxylic group – in position 1 – of another alpha-amino acid

Immunoglobulin

protein produced by B cells, made up of two identical heavy and two identical light chains, held together by interchain disulfide bonds

Hybrid peptide

peptide comprising components of heterologous molecules

Fusion peptide

peptide consisting of (parts of) different proteins covalently linked to each other by a peptide bond

Signal sequence

a 3-60 amino acids stretch that directs the transport of the protein to which it is attached

Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies {(antibodies with enzymatic activity, e.g. abzymes C12N 9/0002)}
Definition statement
This group covers:

Antibodies, immunoglobulins and proteins derived therefrom that bind a specific antigen, and have as minimal structural features an immunoglobulin framework and three CDRs (i.e. a variable domain). In addition, antibody mimetics and scaffolds that bind a specific antigen. Where appropriate, the term antibody as used in these definitions also encompasses said antigen-binding mimetics and scaffolds. The terms antibodies and immunoglobulins are often used interchangeably.

This maingroup covers the following aspects of antibodies:

Structure

Production

Specificity

Cells producing the antibody, e.g. hybridomas producing a monoclonal antibody

DNA/RNA encoding an antibody

  • Therapeutic and prophylactic use
  • Diagnostic use and use for detection
  • Fusion proteins comprising at least the antigen-binding region of an antibody

Antibody mimetics and scaffolds.

References relevant to classification in this group
This group does not cover:

Antibody with enzymatic /catalytic activity, e.g. abzymes

Stabilization of antibody compositions, e.g. for storage or administration

Fusion protein of an Fc-region of an immunoglobulin + a non-antibody protein

Examples of places where the subject matter of this maingroup is covered when specially adapted, used for a particular purpose, or incorporated in a larger system:

Medicinal preparations containing blood products

Medicinal preparations containing peptides

Mixtures of active ingredients without chemical characterization

Stabilization of medicinal preparations comprising antibodies

Medicinal preparations comprising a mixture of an antibody and a non-antibody

Medicinal preparations comprising immunoconjugates

Gene therapy

Antibodies containing fluorescent labels for use in detection in vivo

Antibodies containing NMR labels for use in detection in vivo

Antibodies containing radioactive substances for use in therapy or detection in vivo

Antibodies with enzymatic activity

Immunoassay; biospecific binding assay

Informative references
Attention is drawn to the following places, which may be of interest for search:

Medicinal preparations containing antigens

Stabilization of medicinal preparations comprising antibodies

Medicinal preparations comprising a mixture of an antibody and a non-antibody

Medicinal preparations comprising immunoconjugates

Antibodies containing fluorescent labels for use in detection in vivo

Antibodies containing NMR labels for use in detection in vivo

Antibodies containing radioactive substances for use in therapy or detection in vivo

General methods for the preparation of peptides

Peptides having more than 20 amino acids

Antibodies with enzymatic activity

Immunoassay; biospecific binding assay

Special rules of classification within this group

At least one group is mandatory. Additionally, one or more indexing codes may be given. Both the at least one group and the indexing code(s) are mandatory for relevant and sufficiently disclosed aspects, e.g. for aspects actually disclosed in examples and not just casually claimed or generally referred to in the description. With regard to the specificity of an antibody for an antigen, the "last-place-rule" does not apply.

(1) Antibody and/or fragments or derivatives thereof, i.e. the product per se. Emphasis is on the antigen specificity of the antibody.

NOTE: The specificity of an antibody for a certain antigen (with synonyms) may be found in the regularly updated “keyword/classification index” at the end of this section.

A group in C07K 16/00 (classified according to specificity), see the following examples:

  • C07K 16/08 (against material from viruses)
  • C07K 16/081 or subgroups thereof (against material from DNA viruses)
  • C07K 16/10 or subgroups thereof (against material from RNA viruses)
  • C07K 16/12 or subgroups thereof (against material from bacteria)
  • C07K 16/14 (against material from fungi, algae or lichens)
  • C07K 16/16 (against material from plants)
  • C07K 16/16 (against material from plants)
  • C07K 16/18 (against material from animals or humans)
  • C07K 16/20 (against material from protozoa)
  • C07K 16/22 (against growth factors)
  • C07K 16/24 or subgroups thereof (against cytokines, lymphokines or interferons)
  • C07K 16/26 (against hormones)
  • C07K 16/28 or subgroups thereof (against receptors)
  • C07K 16/30 or subgroups thereof (against tumor antigens)
  • C07K 16/32 (against translation products of oncogenes)
  • C07K 16/34 (against blood group antigens)
  • C07K 16/36 (against blood coagulation factors)
  • C07K 16/38 (against protease inhibitors of peptide structure)
  • C07K 16/38 (against protease inhibitors of peptide structure)
  • C07K 16/40 (against enzymes)
  • C07K 16/42 or subgroups thereof (against immunoglobulins)
  • C07K 16/44 (against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, individual amino acid residues, phosphorylated residues)

Note: If an antigen that, under "normal/benign" conditions, justifies a class for the specifically binding antibody in the C07K 16/08 - C07K 16/28 and C07K 16/34-C07K 16/44 ranges, is disclosed to be (over)expressed under malignant conditions (e.g. in or on a tumor cell), then an additional antibody class in the C07K 16/30 - C07K 16/32 (i.e. antibodies against tumor, resp. oncogene antigens) ranges should be given.

(2) Antibody or fragments or derivatives thereof. Emphasis is on a new technique of the construction of the immunoglobulin molecule or derivative thereof.

C07K 16/00 (general) or C07K 16/005 (phage display)

Optionally a group in C07K 16/00(for the specificity, if in an example)

(3) DNA/RNA encoding an antibody or a fragment thereof.

A group in C07K 16/00(for the specificity)

No Indexing Code used for the aspect of DNA/RNA.

(4) Hybridoma producing a monoclonal antibody. Emphasis is on the antigen specificity of the monoclonal antibody.

A group in C07K 16/00(for the specificity)

No Indexing Code used for aspect of hybridoma.

(5) Hybridoma producing a monoclonal antibody. Emphasis is on the technique of producing the hybridoma.

A group in C12N 5/00(for the hybridoma cell) and/or

A group in C12N 15/00(for the hybridoma technique)

Optionally a group in C07K 16/00(for the specificity, if there is an example)

(6) Fusion protein of (at least an antigen-binding part of) an antibody + a non-antibody protein. Not to be confused with ‘synthebodies’, see further below.

A group in C07K 16/00 (for the specificity of the antibody part)

A group in C07K 14/00 (for the non-antibody part)

Indexing Code C07K 2319/00 (fusion protein)

(7) Fusion protein of an Fc-region of an immunoglobulin + a non-antibody protein.

A group in C07K 14/00 (for the non-antibody part)

Indexing Code C07K 2319/30 (Fc fused to non-Ig)

(8) Chemical conjugate of (at least an antigen-binding part of) an antibody + a toxin or drug.

A group in C07K 16/00 (for the specificity) and

A61K 47/48369 or subgroups thereof (if the antibody contains a drug or toxin for use in therapy in vivo) and/or

A61K 51/10 or subgroups thereof (if the antibody contains a radioactive substance for use in therapy in vivo)

(9) Chemical conjugate of (at least an antigen-binding part of) an antibody + a detectable label.

A group in C07K 16/00 (for the specificity) and

G01N 33/53 or subgroups thereof (if the antibody is for use in detection in vitro) and/or

A61K 51/10 or subgroups thereof (if the antibody contains a radioactive substance for use in detection in vivo) and/or

A61K 49/0058 (if the antibody contains a fluorescent label for use in detection in vivo) and/or

A61K 49/16 (if the antibody contains a nuclear magnetic resonance label for use in detection in vivo)

(10) Therapeutic use of an antibody or a therapeutic composition comprising an antibody.

A group in C07K 16/00 (for the specificity), and

Indexing Code A61K 2039/505 (therapeutic use of an antibody, but only if in an in vivo example (this includes pharmacokinetic studies). Note: Because at the date of classification it is not foreseeable how plausible an in vitro assay will be for the assessment of therapeutic effectiveness, in vitro examples, including those that make in vivo therapeutic effectiveness plausible, should be classified in the C07K 2317/70 series, see below), and/or

optionally Indexing Code A61K 2039/54 (route of administration, but only if important), and/or

optionally Indexing Code A61K 2039/545 (dose, timing or administration schedule, but only if important), and/or

optionally Indexing Code A61K 2039/57 (type of response, e.g. TH1- or TH2-type T cell response).

(11) Therapeutic use of a combination of two or more antibodies or a therapeutic composition comprising two or more antibodies. Said antibodies have an additive or synergistic effect, and the antibodies may be given as a mixture or consecutively. This should not to be confused with a mixture of an antibody with a non-antibody, see below.

A group in C07K 16/00 (for the specificity of the first antibody), and

A group in C07K 16/00 (for the specificity of the second antibody), and

Indexing Code A61K 2039/507 (therapeutic use of an antibody combination. Note: said code may not only be given for an in vivo example, but also if shown in an in vitro example), and/or

Optionally Indexing Code A61K 2039/54 (route of administration, but only if important), and/or

Optionally Indexing Code A61K 2039/545 (dose, timing or administration schedule, but only if important), and/or

Optionally Indexing Code A61K 2039/57 (type of response, e.g. TH1- or TH2-type response).

(12) Therapeutic combinations of antibodies (or fragments thereof) + non-antibody proteins, or compositions comprising these combinations.

A61K 39/395 (or a subgroup thereof), A61K 2300/00; A61K 39/40, A61K 2300/00 or A61K 39/42, A61K 2300/00 as a Combination Set, and

A group in A61K 38/00 (for the non-antibody protein)

A group in C07K 16/00 (for the specificity).

(13) Therapeutic combinations of antibodies (or fragments thereof) + structurally undefined (e.g. functionally defined) compounds, or compositions comprising these combinations.

A61K 39/395 (or a subgroup thereof), A61K 2300/00; A61K 39/40, A61K 2300/00 or A61K 39/42, A61K 2300/00 as a Combination Set, and

A61K 45/06 (for the structurally undefined compound)

A group in C07K 16/00(for the specificity).

(14) Therapeutic combinations of antibodies (or fragments thereof) + blood-derived cells, or compositions comprising these combinations.

A61K 39/395 (or a subgroup thereof), A61K 2300/00; A61K 39/40, A61K 2300/00 or A61K 39/42, A61K 2300/00 as a Combination Set, and

A61K 35/14 (for the blood-derived cells)

A group in C07K 16/00 (for the specificity).

(15) Diagnostic use of an antibody, or a diagnostic composition comprising an antibody. Emphasis is on the antigen specificity, not on the assay technique.

A group in C07K 16/00 (for the specificity)

No Indexing Code used for aspect of diagnosis.

(16) Diagnostic use of an antibody, or a diagnostic composition comprising an antibody. Emphasis is on a new assay technique. The antigen specificity may not be crucial.

G01N 33/53 or subgroups thereof.

A group in C07K 16/00 (for the specificity, if there is an example).

(17) Antibody isolated from eggs. Emphasis is on the isolation technique, not on the antigen specificity.

C07K 16/02 (for the isolation technique from eggs), and

A group in C07K 16/00 (for the specificity, if in an example)

(18) Antibody isolated from eggs. Emphasis is on the antigen specificity, not on the technique of isolation.

A group in C07K 16/00 (for the specificity), and

Indexing Code C07K 2317/11 (antibody isolated from eggs)

(19) Antibody isolated from milk. Emphasis is on the isolation technique, not on the antigen specificity.

C07K 16/04 (for the isolation technique from milk), and

Optionally a group in C07K 16/00 (for the specificity, if in an example)

(20) Antibody isolated from milk. Emphasis is on the antigen specificity, not on the technique of isolation.

A group in C07K 16/00 (for the specificity), and

Indexing Code C07K 2317/12 (antibody isolated from milk)

(21) Antibody isolated from serum. Emphasis is on the isolation technique, not on the antigen specificity.

C07K 16/06 (for the isolation technique from serum), and

Optionally C07K 16/00 (for the specificity, if in an example)

Note: The term "serum" should be interpreted widely and includes blood and plasma as well. In practice, the subgroup C07K 16/065 is used more often and relates to the purification (e.g. by chromatography, filtration) and fragmentation (e.g. by enzymatic digestion) of the immunoglobulin.

(22) Antibody isolated from plants. Emphasis is on the antigen specificity, not on the technique of isolation.

A group in C07K 16/00(for the specificity), and

Indexing Code C07K 2317/13 (antibody isolated from plants)

(23) Antibody characterized by their source of isolation or production. Emphasis is on the protein-expression technique, e.g. to improve yield, purity or glycosylation, e.g. by using specific host-cells, vectors, additives or culture conditions.

A group in C07K 16/00(for the specificity), and

Indexing Code C07K 2317/14 (source of isolation, production)

(24) Antibody according to its taxonomic origin.

A group in C07K 16/00 (for the specificity), and

Indexing Code C07K 2317/20 (general aspects of origin), and/or

Indexing Code C07K 2317/21 (fully primate or fully human, including fully human antibodies produced by transgenic animals, e.g. by Xenomouse®), and/or

Indexing Code C07K 2317/22 (fully camelid), and/or

Indexing Code C07K 2317/23 (fully avian)

(25) Antibody comprising immunoglobulin-regions, -domains or -residues from more than one species, e.g. chimeric, humanized or veneered antibody. Emphasis is on a new technique of construction, not on the antigen specificity.

C07K 16/461…. (for the technique), and

A group in C07K 16/00 (for the specificity, if in an example)

(26) Antibody comprising immunoglobulin-regions, -domains or -residues from more than one species, e.g. chimeric, humanized or veneered antibody. Emphasis is on the antigen specificity, not on the technique of construction.

A group in C07K 16/00 (for the specificity), and

Indexing Code C07K 2317/24 (chimeric, humanized, veneered antibody)

(27) Antibody characterized by general aspects of specificity or valency.

A group in C07K 16/00(for the specificity), and

Indexing Code C07K 2317/30.

(28) Multispecific (i.e. including bispecific) antibody. Emphasis is on a new technique of construction, not on the antigen specificity.

C07K 16/468 or subgroup thereof (for the technique of bispecific antibodies), and

A group in C07K 16/00 (for the first specificity, if in an example), and

A group in C07K 16/00 (for the second specificity, if in an example), and

Optionally a group in C07K 16/00 (for any additional specificity, if in an example)

(29) Multispecific (i.e. including bispecific) antibody. Emphasis is on the antigen specificity, not on the technique of construction.

A group in C07K 16/00 (for the first specificity), and

A group in C07K 16/00 (for the second specificity), and

Optionally, a group in C07K 16/00 (for any additional specificity, if in an example), and

Indexing Code C07K 2317/31 (multispecific antibody)

(30) Antibody specific for a neo-epitope formed by a complex, e.g. antibody-antigen, ligand-receptor. The antibody is monospecific, not bispecific !

A group in C07K 16/00 (for the first component of the complex), and

A group in C07K 16/00(for the second component of the complex), and

Indexing Code C07K 2317/32 (to indicate specificity for the complex)

(31) Antibody characterized by its crossreactivity (e.g. for species or epitope) or lack of crossreactivity.

A group in C07K 16/00 (for the specificity), and

Indexing Code C07K 2317/33 (for the aspect of crossreactivity or explicit lack thereof).

(32) Antibody characterized by its specificity for a well-defined epitope or immunogen which is either linear and shorter than 20 amino acid residues, or conformational and defined by amino acid residues.

A group in C07K 16/00 (for the specificity for the antigen), and

Indexing Code C07K 2317/34 (linear epitope <20 AA residues or conformational epitope defined by AA residues)

(33) Antibody characterized by its valency, and wherein the fact that the molecule is monovalent, bivalent or multivalent is an important feature.

A group in C07K 16/00 (for the specificity), and

Indexing Code C07K 2317/35 (for the aspect of valency, but only if important).

(34) Antibody characterized by its post-translational modification.

A group in C07K 16/00 (for the specificity), and

Indexing Code C07K 2317/40 (for the aspect of post-translational modification).

(35) Antibody wherein the presence, absence or modification by glycosylation, sialylization, fucosylation is an important feature.

A group in C07K 16/00 (for the specificity), and

Indexing Code C07K 2317/41 (glycosylation, sialylization, fucosylation)

(36) Antibody characterized by immunoglobulin fragments.The mere provision of an amino acid or nucleotide sequence is not enough to justify one or more of the following codes:

C07K 16/00 (for the specificity of the antigen binding part), and

Indexing Code C07K 2317/50 (fragments in general), and/or

Indexing Code C07K 2317/51 (complete heavy chain or Fd fragment), and/or

Indexing Code C07K 2317/515 (complete light chain), and/or

Indexing Code C07K 2317/52 (Fc or constant region, isotype), and/or

Indexing Code C07K 2317/522 (CH1), and/or

Indexing Code C07K 2317/524 (CH2), and/or

Indexing Code C07K 2317/526 (CH3), and/or

Indexing Code C07K 2317/528 (CH4), and/or

Indexing Code C07K 2317/53 (hinge), and/or

Indexing Code C07K 2317/54 (F(ab’)2), and/or

Indexing Code C07K 2317/55 (Fab or Fab’), and/or

Indexing Code C07K 2317/56 (variable = Fv), and/or

Indexing Code C07K 2317/565 (CDR), and/or

Indexing Code C07K 2317/567 (framework = FR), and/or

Indexing Code C07K 2317/569 (single domain = sdAb or dAb)

Note: The mere provision of an amino acid or nucleotide sequence per se of the above fragment is not enough to justify one or more of the above-mentioned indexing codes, unless said fragment is actually manufactured or modified.

Note: If features of both CDRs (or individual residues therein) and FRs (or individual residues therein) are modified, then both the C07K 2317/565 and C07K 2317/567 codes should be given, and not the general C07K 2317/56 code. The C07K 2317/56 code should be given if the focus is on the intact VH and/or VL domain(s).

Note: Indexing codes in the C07K 2317/522-C07K 2317/53 series should only be given for features, e.g. modifications, concerning these specific domains; otherwise the C07K 2317/52 code should be given. Said specific domains need not necessarily be in isolated form, but may be in the context of their immunoglobulin molecule or fragments thereof.

(37) Antibody characterized by non-natural combinations of immunoglobulins or fragments.This includes fusion proteins and chemically linked immunoglobulins or their fragments. Excluded are chimeric, humanized or veneered antibodies (see above).

A group in C07K 16/00(for the specificity), and

Indexing Code C07K 2317/60 (general aspects), and/or

Indexing Code C07K 2317/622 (single chain = scFv), and/or

Indexing Code C07K 2317/624 (disulfide stabilized variable = dsFv), and/or

Indexing Code C07K 2317/626 (diabody, triabody), and/or

Indexing Code C07K 2317/64 (comprising a combination of variable region and constant region components), and/or

Indexing Code C07K 2317/66 (comprising a swap of domains, e.g. CH3-CH2, VH-CL, VL-CH1).

Optionally Indexing Code C07K 2319/00 (if fusion protein)

(38) Antibody characterized by an effect upon binding to a cell or to an antigen

A group in C07K 16/00(for the specificity), and

Indexing Code C07K 2317/71 (decreased effector function due to an Fc-modification), and/or

Indexing Code C07K 2317/72 (increased effector function due to an Fc-modification), and/or

Indexing Code C07K 2317/73 (induction of cell death, e.g. apoptosis, necrosis; inhibition of cell proliferation), and/or

Indexing Code C07K 2317/732 (antibody-dependent cellular cytotoxicity (ADCC)), and/or

Indexing Code C07K 2317/734 (complement-dependent cytotoxicity (CDC)), and/or

Indexing Code C07K 2317/74 (induction of cell proliferation), and/or

Indexing Code C07K 2317/75 (agonist effect on antigen), and/or

Indexing Code C07K 2317/76 (antagonist effect on antigen, neutralization, inhibition of binding), and/or

Indexing Code C07K 2317/77 (internalization into the cell).

(39) Antibody characterized by remaining in the (producing) cell, i.e. intracellular antibody = intrabody

A group in C07K 16/00(for the specificity), and

Indexing Code C07K 2317/80 (general aspects), and/or

Indexing Code C07K 2317/81 (intracellular antibody functional in the ER or Golgi apparatus), and/or

Indexing Code C07K 2317/82 (intracellular antibody functional in the cytoplasm, the nucleus, the mitochondria, the inner part of the cell membrane)

(40) Antibody characterized by(pharmaco)kinetic aspects or stability of the immunoglobulin.

A group in C07K 16/00(for the specificity), and

Indexing Code C07K 2317/90 (general aspects), or

Indexing Code C07K 2317/92 (for affinity (KD), association rate (Ka), dissociation rate (Kd), EC50 value), or

Indexing Code C07K 2317/94 (in vivo stability, e.g. half-life, pH-, temperature- or enzyme-resistance; Note: for in vitro/pretreatment storage stability see A61K 39/39591).

(41) Antibody mimetics and scaffolds.

A group in C07K 16/00(for the specificity of the inserted antigen binding sequences from antibodies), and

Indexing Code C07K 2318/00 (general aspects of antibody mimetics and scaffolds)

(42) Immunoglobulin or domain(s) thereof as scaffolds for inserted non-immunoglobulin peptide sequences, e.g. for vaccination purposes, e.g. synthebody.

C07K 14/00(for the non-immunoglobulin protein that is inserted), and

C07K 16/00(for the specificity of the immunoglobulin scaffold), and

Indexing Code C07K 2318/10 (to indicate the combination of immunoglobulin scaffold molecules with inserted non-immunoglobulin peptide sequences)

(43) Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region, antibody mimetics.

A group in C07K 14/00(for the non-immunoglobulin protein that provides the scaffold).

A group in C07K 16/00(for the antibody-like specificity of the scaffold molecule).

Indexing Code C07K 2318/20 (for scaffold molecules with antigen binding properties)

Guide to the specificity of an antibody for a certain antigen (with synonyms) - KEYWORD/CLASSIFICATION INDEX (KCI)

  • C07K 16/22 - Growth factors, growth regulators
  • C07K 16/22 - Activin
  • C07K 16/22 - Activin A
  • C07K 16/22 - Activin B
  • C07K 16/22 - Activin C
  • C07K 16/22 - Activin D
  • C07K 16/22 - Activin E
  • C07K 16/22 - Adrenomedullin
  • C07K 16/22 - Angiogenin
  • C07K 16/22 - Angiopoietin
  • C07K 16/22 - Angiopoietin 1, Ang-1, Angpt-1, Ang1
  • C07K 16/22 - Angiopoietin 2, Ang-2, Angpt-2, Ang2
  • C07K 16/22 - Angiopoietin 3, Ang-3, Angpt-3, Ang3
  • C07K 16/22 - Angiopoietin 4, Ang-4, Angpt-4, Ang4
  • C07K 16/22 - Angiopoietin-like protein 2, Angptl-2, ARP2
  • C07K 16/22 - Angiopoietin-like protein 3, Angptl-3, ARP3
  • C07K 16/22 - Angiopoietin-like protein 4, Angptl-4, PGAR, BK89, FIAF, fasting- induced adipose factor, HFARP, hepatic fibrinogen/angiopoietin-related protein, FDRG, fibrinogen-domain, TANGO115, PPARgamma, peroxisome proliferator-activated angiopoietin-related gamma
  • C07K 16/22 - Angiopoietin-like protein 5, Angptl-5, ARP5
  • C07K 16/22 - Angiopoietin-like protein 6, Angptl-6, ARP6
  • C07K 16/22 - Angiopoietin-like protein 7, Angptl-7, ARP7
  • C07K 16/22 - Artemin, ARTN
  • C07K 16/22 - BDNF, brain-derived neurotrophic factor
  • C07K 16/22 - bone-inducing factor
  • C07K 16/22 - bone morphogenetic factor, bone morphogenetic protein, BMP, morphogen
  • C07K 16/22 - ChM-I, ChM-1, chondromodulin 1
  • C07K 16/22 - CTGF, connective tissue growth factor
  • C07K 16/22 - CTGF-1, connective tissue growth factor 1
  • C07K 16/22 - CTGF-2, connective tissue growth factor 2
  • C07K 16/22 - Desert hedgehog, Dhh
  • C07K 16/22 - EGF, epidermal growth factor, urogastrone
  • C07K 16/22 - EGFL7, EGF-like domain multiple 7, EGF like domain 7, Neu1, Zneu1, VE-statin, vascular endothelial statin, RP11-25M1.2, epidermal growth factor like domain 7
  • C07K 16/22 - Epiregulin, ER, EREG
  • C07K 16/22 - EPO, erythropoietin
  • C07K 16/22 - FGF, fibroblast growth factor
  • C07K 16/22 - FGF-1, fibroblast growth factor 1, acidic FGF, aFGF, acidic fibroblast growth factor, retinal-derived growth factor, prostatropin, heparin- binding growth factor alpha, HBGF-alpha, eye-derived growth factor 2, ECGF, endothelial cell growth factor, brain-derived growth factor, astroglial growth factor 1, delta-15 beta endothelial growth factor, HBGF-1, heparin-binding growth factor 1
  • C07K 16/22 - FGF-2, fibroblast growth factor 2, basic FGF, bFGF, basic fibroblast growth factor, macrophage growth factor, hepatoma-derived growth factor, heparin-binding growth factor beta, eye-derived growth factor 1, chondrosarcoma-derived growth factor, cartilage-derived growth factor, astroglial growth factor 2
  • C07K 16/22 - FGF-3, fibroblast growth factor 3, INT-2 oncogene
  • C07K 16/22 - FGF-4, fibroblast growth factor 4, heparin-binding secretory transforming factor, HST-1, human transforming protein, HST, human Kaposi sarcoma oncogene
  • C07K 16/22 - FGF-5, fibroblast growth factor 5
  • C07K 16/22 - FGF-6, fibroblast growth factor 6, HST-2
  • C07K 16/22 - FGF-7, fibroblast growth factor 7, SDGF-3, spleen-derived growth factor 3, HBGF-7, heparin-binding growth factor 7
  • C07K 16/22 - FGF-8, fibroblast growth factor 8, AIGF, androgen-induced growth factor
  • C07K 16/22 - FGF-9, fibroblast growth factor 9, GAF, glia activating factor
  • C07K 16/22 - FGF-10, fibroblast growth factor 10
  • C07K 16/22 - FGF-11, fibroblast growth factor 11, FHF-1, FGF homologous factor 1, fibroblast growth factor homologous factor 1
  • C07K 16/22 - FGF-12, fibroblast growth factor 12, FHF-2, FGF homologous factor 2, fibroblast growth factor homologous factor 2, KGF-2, keratinocyte growth factor 2
  • C07K 16/22 - FGF-13, fibroblast growth factor 13, FHF-3, FGF homologous factor 3, fibroblast growth factor homologous factor 3
  • C07K 16/22 - FGF-14, fibroblast growth factor 14, FHF-4, FGF homologous factor 4, fibroblast growth factor homologous factor 4
  • C07K 16/22 - FGF-15, fibroblast growth factor 15
  • C07K 16/22 - FGF-CX, fibroblast growth factor CX
  • C07K 16/22 - Fibulin 5, FBLN-5, DANCE, EVEC
  • C07K 16/22 - GDF-8, growth and differentiation factor 8, myostatin, mstn
  • C07K 16/22 - GDF-15, growth and differentiation factor 15, MIC-1, macrophage inhibitory cytokine 1, PDF, prostate-derived factor, PLAB, placental bone morphogenetic protein
  • C07K 16/22 - GDNF, glial-derived neurotrophic factor, glial cell-derived neurotrophic factor
  • C07K 16/22 - Glial growth factor
  • C07K 16/22 - HB-EGF, heparin-binding EGF-like growth factor
  • C07K 16/22 - HBGF-2, heparin-binding growth factor 2
  • C07K 16/22 - Hedgehog, Hh
  • C07K 16/22 - Heregulin, HRG, Neu differentiation factor, NDF
  • C07K 16/22 - Heregulin alpha, HRG-alpha,
  • C07K 16/22 - Heregulin beta1, HRG-beta1
  • C07K 16/22 - Heregulin beta2, HRG-beta2
  • C07K 16/22 - Heregulin beta2-like, HRG-beta2-like
  • C07K 16/22 - Heregulin gamma, HRG-gamma
  • C07K 16/22 - Indian hedgehog, Ihh
  • C07K 16/22 - Insulin-like growth factors, IGF, somatomedins
  • C07K 16/22 - Insulin-like growth factor 1, IGF-1
  • C07K 16/22 - Insulin-like growth factor 2, IGF-2
  • C07K 16/22 - HGF, hepatocyte growth factor
  • C07K 16/22 - MK, midkine, amphiregulin associated protein, ARAP, NEGF2, neurite growth promoting factor 2, neurite outgrowth promoting factor 2, neurite outgrowth promoting protein.
  • C07K 16/22 - MSP, macrophage stimulating protein, HGFL, hepatocyte growth factor- like, MST-1
  • C07K 16/22 - Netrin 1
  • C07K 16/22 - Netrin 2
  • C07K 16/22 - Netrin 3
  • C07K 16/22 - Netrin 4
  • C07K 16/22 - neuregulin
  • C07K 16/22 - NGF, nerve growth factor
  • C07K 16/22 - NT-3, neurotrophin 3
  • C07K 16/22 - NT-4/5, neurotrophin 4/5
  • C07K 16/22 - neurturin, NTN, NRTN
  • C07K 16/22 - osteogenin
  • C07K 16/22 - PCDGF, PC cell derived growth factor, epithelin/granulin precursor, gp88
  • C07K 16/22 - Persephin, PSN, PSPN
  • C07K 16/22 - PDGF, platelet derived growth factor
  • C07K 16/22 - PDGF-A, platelet derived growth factor A
  • C07K 16/22 - PDGF-B, platelet derived growth factor B
  • C07K 16/22 - PDGF-C, platelet derived growth factor C, VEGF-R, zVEGF3
  • C07K 16/22 - PDGF-D, platelet derived growth factor D
  • C07K 16/22 - PlGF, placental growth factor
  • C07K 16/22 - Prokineticin 1, pk1, prok1, EG-VEGF, endocrinal gland-derived vascular endothelial growth factor
  • C07K 16/22 - Prokineticin 2, pk2, prok2, bv8
  • C07K 16/22 - RGM, repulsive guidance molecule
  • C07K 16/22 - RGM-A, repulsive guidance molecule A
  • C07K 16/22 - RGM-B, repulsive guidance molecule B
  • C07K 16/22 - RGM-C, repulsive guidance molecule C
  • C07K 16/22 - Sclerostin
  • C07K 16/22 - SKCG-1, SKCG1
  • C07K 16/22 - Sonic hedgehog, Shh
  • C07K 16/22 - TGF, transforming growth factor
  • C07K 16/22 - TGFalpha, TGF alpha, transforming growth factor alpha, TGFa
  • C07K 16/22 - TGFbeta, TGF beta, transforming growth factor beta, TGFb
  • C07K 16/22 - VEGF, vascular endothelial growth factor
  • C07K 16/22 - VEGF-C, vascular endothelial growth factor C, Flt4 ligand, Flt4-L
  • C07K 16/22 - VRP, VEGF-related protein
  • C07K 16/22 - WISP-1
  • C07K 16/22 - WISP-2
  • C07K 16/22 - WISP-3
  • C07K 16/22 - Wnt1, wnt-1
  • C07K 16/22 - Wnt2, wnt-2
  • C07K 16/22 - Wnt3, wnt-3
  • C07K 16/22 - Wnt5A, wnt-5A
  • C07K 16/22 - Wnt7A, wnt-7A
  • C07K 16/22 - Wnt7B, wnt-7B
  • C07K 16/22 - Wnt8B, wnt-8B
  • C07K 16/22 - Wnt10B, wnt-10B
  • C07K 16/22 - Wnt11, wnt-11
  • C07K 16/22 - Wntx, wnt-x
  • C07K 16/24 - Cytokines, lymphokines, chemokines, interferons
  • C07K 16/24 - Calgranulin A, MRP8, S100A8, calcium binding protein A8, CABP-P8, 60B8-B, cystic fibrosis antigen
  • C07K 16/24 - Calgranulin B, MRP14, S100A9, calcium binding protein A9
  • C07K 16/24 - CXCL1, GROalpha, GRO-alpha, growth-related oncogene alpha, MGSAalpha, MGSA-alpha, melanoma growth stimulatory activity alpha, NAP-3, neutrophil-activating peptide 3, Gro-1 alpha
  • C07K 16/24 - CXCL2, GRObeta, GRO-beta, growth-related oncogene beta, MGSAbeta, MGSA-beta, melanoma growth stimulatory activity beta, MIP-2 alpha, macrophage inflammatory protein 2 alpha, Gro-1 beta
  • C07K 16/24 - CXCL3, GROgamma, GRO-gamma, growth-related oncogene gamma, MGSAgamma, MGSA-gamma, melanoma growth stimulatory activity gamma, MIP-2 beta, macrophage inhibitory protein 2 beta, Gro-1 gamma
  • C07K 16/24 - CXCL4, PF4, plasma factor 4, oncostatin A
  • C07K 16/24 - CXCL5, ENA-78, epithelial cell-derived neutrophil attractant 78
  • C07K 16/24 - CXCL6, GCP-2, granulocyte chemotactic peptide 2, LPS-induced CXC, LIX
  • C07K 16/24 - CXCL7, NAP-2, neutrophil-activating protein 2, CTAP-3, connective tissue activating protein 3, LA-PF4, low affinity platelet factor 4, PBP, platelet basic protein, beta thromboglobulin
  • C07K 16/24 - CXCL9, Mig, monokine induced by IFN-gamma, CRG-10, cytokine responsive gene 10
  • C07K 16/24 - CXCL10, IP-10, interferon-inducible protein 10, immune protein 10, CRG-2, cytokine responsive gene 2
  • C07K 16/24 - CXCL11, I-TAC, interferon-inducible T cell alpha chemoattractant, IP-9, interferon-gamma inducible protein 9
  • C07K 16/24 - CXCL12, SDF-1, stromal cell-derived factor 1, PBSF, pre-B cell growth stimulating factor
  • C07K 16/24 - CXCL13, BLC, B lymphocyte chemoattractant, BCA-1, B cell attracting chemokine 1
  • C07K 16/24 - CXCL14, BRAK, CXC chemokine in breast and kidney, BMAC, B cell and monocyte activating chemokine, bolekine
  • C07K 16/24 - CXCL15, WECHE, weird chemokine
  • C07K 16/24 - CCL1, I-309, TCA-3, p500
  • C07K 16/24 - CCL2, MCP-1, monocyte chemoattractant protein 1, MCAF, monocyte chemoattractant and activating factor, GDCF, glioma cell-derived chemotactic factor, tumor necrosis factor-stimulated gene sequence 8, monocyte chemotactic protein 1
  • C07K 16/24 - CCL3, MIP-1alpha, MIP-1 alpha, macrophage inflammatory protein 1alpha, macrophage inflammatory protein 1 alpha, GOS-19, G0/G1 switch gene
  • C07K 16/24 - CCL4, MIP-1beta, MIP-1 beta, macrophage inflammatory protein 1beta, macrophage inflammatory protein 1 beta, ACT-2, immune activation gene 2
  • C07K 16/24 - CCL5, RANTES, regulated upon activation normal T cell expressed and secreted, EoCP-1, eosinophil chemotactic polipeptide 1, SIS-delta, small inducible secreted chemokine delta
  • C07K 16/24 - CCL6, C10, MRP-1, macrophage inflammatory protein-related protein 1
  • C07K 16/24 - CCL7, MCP-3, monocyte chemoattractant protein 3, MARC, mast cell activation-related chemokine, NC28
  • C07K 16/24 - CCL8, MCP-2, monocyte chemoattractant protein 2
  • C07K 16/24 - CCL9, MIP-1gamma, MIP-1 gamma, macrophage inflammatory protein 1gamma, macrophage inflammatory protein 1 gamma, CCF18
  • C07K 16/24 - CCL10
  • C07K 16/24 - CCL11, eotaxin
  • C07K 16/24 - CCL12, MCP-5, monocyte chemotactic protein 5
  • C07K 16/24 - CCL13, MCP-4, monocyte chemotactic protein 4
  • C07K 16/24 - CCL14, HCC-1, hemofiltrate CC chemokine 1, M-CIF, macrophage colony inhibitory factor
  • C07K 16/24 - CCL15, MIP-5, macrophage inflammatory protein 5, HCC-2, hemofiltrate CC chemokine 2, NCC-3, leukotactin 1
  • C07K 16/24 - CCL16, LEC, NCC-4, HCC-4, hemofiltrate CC chemokine 4, new CC chemokine 4, liver-expressed chemokine, monotactin 1
  • C07K 16/24 - CCL17, TARC, ABCD-2, thymus and activation-regulated cytokine
  • C07K 16/24 - CCL18, DC-CK1, PARC, AMAC-1, dendritic cell-derived chemokine 1, pulmonary and activation-regulated chemokine, alternative activated macrophage-associated CC chemokine
  • C07K 16/24 - CCL19, ELC, exodus-3, EBI-1 ligand chemokine
  • C07K 16/24 - CCL20, LARC, exodus-1, liver and activation-regulated chemokine
  • C07K 16/24 - CCL21, SLC, exodus-2, 6Ckine, secondary lymphoid tissue chemokine
  • C07K 16/24 - CCL22, MDC, STCP-1, DC/B-CK, macrophage-derived chemokine, stimulated T cell chemoattractant protein 1
  • C07K 16/24 - CCL23, MPIF-1, myeloid progenitor inhibitory factor 1, chemokine beta8, chemokine beta 8
  • C07K 16/24 - CCL24, MPIF-2, eotaxin-2, myeloid progenitor inhibitory factor 2, chemokine beta6, chemokine beta 6
  • C07K 16/24 - CCL25, TECK, thymus-expressed chemokine
  • C07K 16/24 - CCL26, MIP-4alpha, MIP-4 alpha, TSC-1, eotaxin-3, macrophage inflammatory protein 4alpha, macrophage inflammatory protein 4 alpha, thymic stroma chemokine 1
  • C07K 16/24 - CCL27, CTACK, MILC, ILC, cutaneous T cell attracting chemokine, ALP, skinkine, eskine
  • C07K 16/24 - CCL28, MEC, mucosa-associated epithelial chemokine
  • C07K 16/24 - CCL3-L1, MIP-1alphaP, MIP1AP, LD78beta
  • C07K 16/24 - Chemerin, RARRES2, RARRES-2, retinoic acid receptor responder 2, TIG2, TIG-2, tazarotene induced gene 2 product
  • C07K 16/24 - CK alpha 5, CKalpha-5, chemokine alpha 5
  • C07K 16/24 - CK alpha 6, CKalpha-6, chemokine alpha 6
  • C07K 16/24 - endokine alpha
  • C07K 16/24 - HMGB1, high mobility group box protein 1, HMG-1, high mobility group protein 1
  • C07K 16/24 - HMGB2, high mobility group box protein 2, HMG-2, high mobility group protein 2
  • C07K 16/24 - HMGB3, high mobility group box protein 3
  • C07K 16/24 - HMGB8, high mobility group box protein 8
  • C07K 16/24 - HMGB17, high mobility group box protein 17
  • C07K 16/24 - HMGBI, high mobility group box protein I
  • C07K 16/24 - HMGBY, high mobility group box protein Y
  • C07K 16/24 - HMGBI(Y), high mobility group box protein I(Y)
  • C07K 16/24 - HMGBI-C, high mobility group box protein I-C
  • C07K 16/24 - IRAP, interleukin receptor antagonist protein
  • C07K 16/24 - Limitin
  • C07K 16/24 - MIF, MMIF, macrophage migration inhibitory factor
  • C07K 16/24 - OPN, osteopontin
  • C07K 16/24 - SCF, stem cell factor, c-kit ligand
  • C07K 16/24 - SMAF1, SMAF-1, suppressive macrophage activation factor 1
  • C07K 16/24 - SMAF2, SMAF-2, suppressive macrophage activation factor 2
  • C07K 16/24 - thrombopoietin, TPO, MPL ligand
  • C07K 16/24 - XCL1, lymphotactin, Ltn, Lptn, SCM-1alpha, SCM-1 alpha, single C motif 1alpha, ATAC, activation-induced T cell-derived and chemokine related
  • C07K 16/24 - XCL2, SCM-1beta, SCM-1 beta, single C motif 1beta
  • C07K 16/24 - zalpha11 ligand
  • C07K 16/24 - Zcyto10
  • C07K 16/241 - TNF, tumor necrosis factor, tumour necrosis factor
  • C07K 16/241 - CD250, TNFalpha, TNF alpha, tumor necrosis factor alpha, tumour necrosis factor alpha, cachectin, TNFSF2, tumor necrosis factor (ligand) superfamily member 2
  • C07K 16/242 - TNFbeta, TNF beta, tumor necrosis factor beta, tumour necrosis factor beta, LTalpha, LT alpha, lymphotoxin alpha, TNFSF1, tumor necrosis factor (ligand) superfamily member 1
  • C07K 16/242 - LTbeta, LT beta, lymphotoxin beta, p33, TNFC, TNFSF3, tumor necrosis factor (ligand) superfamily member 3
  • C07K 16/243 - CSF, colony stimulating factors
  • C07K 16/243 - G-CSF, granulocyte colony stimulating factor, granulocyte CSF, CSF3, CSF-3
  • C07K 16/243 - GM-CSF, granulocyte-macrophage colony stimulating factor, granulocyte-macrophage CSF.
  • C07K 16/243 - M-CSF, macrophage colony stimulating factor, macrophage CSF, CSF1, CSF-1
  • C07K 16/244 - IL, interleukin
  • C07K 16/244 - IL-3, interleukin-3, HCGF, MCGF, multi-SCF
  • C07K 16/244 - IL-5, interleukin-5, BCGF-2, BCDF, Eo-CSF
  • C07K 16/244 - IL-7, interleukin-7, PBGF, LP-1
  • C07K 16/244 - IL-8, interleukin-8, CXCL8, NAP-1, neutrophil activating protein 1, NAF, neutrophil-activating factor, LAI, leukocyte adhesion inhibitor, GCP, granulocyte chemotactic protein, ENAP-beta, endothelial cell neutrophil-activating peptide
  • C07K 16/244 - IL-9, interleukin-9, MCGF
  • C07K 16/244 - IL-10, interleukin-10, CSIF, TGIF
  • C07K 16/244 - IL-11, interleukin-11, megakaryocyte CSF
  • C07K 16/244 - IL-12, interleukin-12, p40p35
  • C07K 16/244 - IL-12A, interleukin-12A
  • C07K 16/244 - IL-12B, interleukin-12B
  • C07K 16/244 - IL-13, interleukin-13, NC30, p600
  • C07K 16/244 - IL-14, interleukin-14, HMW-BCGF, high-molecular weight B cell growth factor, 60K-BCGF, Namalwa BCGF
  • C07K 16/244 - IL-15, interleukin-15, IL-T
  • C07K 16/244 - IL-16, interleukin-16, LCF, lymphocyte chemoattractant factor
  • C07K 16/244 - IL-17, interleukin-17, CTLA-8
  • C07K 16/244 - IL-17B, interleukin-17B
  • C07K 16/244 - IL-17C, interleukin-17C
  • C07K 16/244 - IL-17D, interleukin-17D
  • C07K 16/244 - IL-17E, interleukin-17E
  • C07K 16/244 - IL-17F, interleukin-17F
  • C07K 16/244 - IL-18, interleukin-18, IGIF, IFN-gamma inducing factor
  • C07K 16/244 - IL-19, interleukin-19
  • C07K 16/244 - IL-20, interleukin-20, zcyto10
  • C07K 16/244 - IL-21, interleukin-21
  • C07K 16/244 - IL-22, interleukin-22, IL-TIF, IL-10 related T cell derived inducible factor
  • C07K 16/244 - IL-23, interleukin-23, p19p40
  • C07K 16/244 - IL-23 p19 subunit, IL-B30
  • C07K 16/244 IL-24, interleukin-24, ST16, suppression of tumorigenicity 16, MDA- 7, melanoma differentiation associated gene 7, mob-5 (rat), c49a (rat), FISP (mouse)
  • C07K 16/244 - IL-25, interleukin-25, SF20
  • C07K 16/244 - IL-26, interleukin-26, AK155, ML-1 (?)
  • C07K 16/244 - IL-27, interleukin-27, EBI3, Epstein-Barr virus-induced gene 3
  • C07K 16/244 - IL-28A, interleukin-28A, IFN lambda 1
  • C07K 16/244 - IL-28B, interleukin 28B, IFN lambda 2
  • C07K 16/244 - IL-29, interleukin-29, IFN lambda 3
  • C07K 16/244 - IL-30, interleukin-30, p28
  • C07K 16/244 - IL-31, interleukin-31
  • C07K 16/244 - IL-32, interleukin-32, NK4, TAIF
  • C07K 16/244 - IL-33, interleukin-33, IL-100, interleukin-100
  • C07K 16/244 - IL-50, interleukin-50, TSLP, thymic stromal lymphopoietin
  • C07K 16/244 - LIF, leukemia inhibitory factor, myeloid differentiation stimulating factor, MDSF, cholinergic differentiation factor, D factor, emfilermin, AM424, AMRAD
  • C07K 16/245 - IL-1, interleukin-1, APPIF, adherence-promoting factor, acute phase protein inducing factor, BCDF, B cell differentiation factor
  • C07K 16/245 - IL-1alpha, LAF, MCF, IL-1a
  • C07K 16/245 - IL-1beta, IFN-beta-inducing factor, OAF, catabolin, IL-1b
  • C07K 16/246 - IL-2, interleukin-2, T cell growth factor, blastogenic factor, LMF, lymphocyte mitogenic factor, LPF, lymphocyte proliferation factor, SCIF, secondary cytotoxic T cell inducing factor, TDF, thymocyte differentiation factor, TMF, thymocyte mitogenic factor, T cell maturation factor, T cell mitogenic factor, TSF, thymocyte stimulation factor
  • C07K 16/247 - IL-4, interleukin-4, IaIF, (MHC class II) Ia inducing factor, BCDF epsilon, BCDF gamma, B cell differentiation factor epsilon, B cell differentiation factor gamma, BCGF gamma, B cell growth factor gamma, BCGF-1, B cell growth factor 1, BSF-1, B cell stimulating factor 1, HCGF, Hodgkin's cell growth factor, IgE-EF, IgE enhancing factor, IgG1 enhancing factor, LMW-BCGF, low molecular weight B cell growth factor, MCGF-2, mast cell growth factor 2, MFF, macrophage fusion factor, TCGF-1, T cell growth factor 2
  • C07K 16/248 - IL-6, interleukin-6, 26 kD protein, BCDF, B cell differentiation factor, BCSF, B cell stimulating factor, BSF-2, B cell stimulating factor 2, CDF, cytotoxic T cell differentiation factor, CPA, CSF-309, DIF, FDGI, FSF, fibronectin stimulating factor, HGF, hybridoma growth factor, HGI, HPGF, HSF, hepatocyte stimulating factor, IFNbeta2, IFN beta 2, interferon beta 2, ILHP1, L-HGF, MGI-2A, MGF, myeloma growth factor, NKAF, natural killer cell activating factor, PCTGF, plasmacytoma growth factor, TAF, T cell activating factor, thymocyte growth factor, TSF, thymocyte stimulating factor
  • C07K 16/248 - OSM, oncostatin
  • C07K 16/249 - IFN, interferons
  • C07K 16/249 - IFNalpha, IFN-alpha, interferon alpha, alpha interferon, IFNa
  • C07K 16/249 - IFNbeta, IFN-beta, interferon beta, beta interferon, IFNb
  • C07K 16/249 - IFNgamma, IFN-gamma, interferon gamma, gamma interferon, IFNg
  • C07K 16/2803 - CD7, gp40
  • C07K 16/2803 - CD19, B4
  • C07K 16/2803 - CD22, BL-CAM, Lyb8 (mouse), Lyb-8 (mouse), siglec-2, sialic acid-binding Ig-related lectin 2
  • C07K 16/2803 - CD31, endocam, myelomonocytic differentiation antigen, PECAM-1, platelet endothelial cell adhesion molecule 1, (platelet) gpIIa
  • C07K 16/2803 - CD33, gp67, siglec-3, sialic acid-binding Ig-related lectin 3
  • C07K 16/2803 - CD47, gp42, GR63, IAP, OA3, 1D8
  • C07K 16/2803 - CD48, BCM1, blast-1, HuLy-M3, OX-45 (rat)
  • C07K 16/2803 - CD56, Leu19, Leu-19, L1CAM, L1-CAM, neural cell adhesion factor L1, NCAM, neural cell adhesion molecule, NKH1, NKH-1, Ng-CAM, 8D9
  • C07K 16/2803 - CD66a, BGP, biliary glycoprotein, CEACAM1, CEACAM-1, carcinoembryonic antigen-related cell adhesion molecule 1
  • C07K 16/2803 - CD66b, CD67, CGM6, NCA-95, p100, CEACAM8, CEACAM-8, carcinoembryonic antigen-related cell adhesion molecule 8
  • C07K 16/2803 - CD66c, NCA, NCA-50/90, CAECAM6, CEACAM-6, carcinoembryonic antigen-related cell adhesion molecule 6
  • C07K 16/2803 - CD66d, CGM1, CEACAM3, CEACAM-3, carcinoembryonic antigen-related cell adhesion molecule 3
  • C07K 16/2803 - CD66f, PSG, pregnancy specific protein, SP-1, PSG1, PSG-1
  • C07K 16/2803 - CD79, B cell (antigen) receptor, BCR
  • C07K 16/2803 - CD79a, Igalpha, Ig alpha, MB1, mb-1, Iga
  • C07K 16/2803 - CD79b, Igbeta, Ig beta, MB2, mb-2, B29, Igb
  • C07K 16/2803 - CD83, HB15
  • C07K 16/2803 - CD85, LIR, GH1/75, VMP-55, LILR, leukocyte immunoglobulin-like receptor
  • C07K 16/2803 - CD85a, LIR3, LIR-3, LIR-PBM17, ILT5, LILRB3, Ig-like transcript 5, ILT-5
  • C07K 16/2803 - CD85b, ILT8, ILT-8
  • C07K 16/2803 - CD85c, LIR-8, LIR-PBMNEW
  • C07K 16/2803 - CD85d, LIR2, LIR-2, MIR10, ILT4, LIR-PBM8, LILRB2, ILT-4
  • C07K 16/2803 - CD85e, LIR4, LIR-4, LIR-PBM25, HM43, ILT6, ILT-6
  • C07K 16/2803 - CD85f, ILT11, ILT-11
  • C07K 16/2803 - CD85g, ILT7, ILT-7
  • C07K 16/2803 - CD85h, LIR-7, LIR-7, LIR-PBMHH, ILT-1, ILT1, Ig-like transcript 1
  • C07K 16/2803 - CD85i, LIR6, LIR-6
  • C07K 16/2803 - CD85j, LIR-1, LIR-18A3, LIR-P3G2, ILT-2, ILT2, Ig-like transcript 2, MIR7, LILRB1
  • C07K 16/2803 - CD85k, LIR-5, LIR-PBM2, HM18, LILRB5, ILT3, ILT-3, Ig-like transcript 3
  • C07K 16/2803 - CD85l, ILT9, ILT-9, Ig-like transcript 9
  • C07K 16/2803 - CD85m, ILT10, ILT-10, Ig-like transcript 10
  • C07K 16/2803 - CD90, Thy1, Thy-1
  • C07K 16/2803 - CD96, TACTILE
  • C07K 16/2803 - CD100, semaphorin 4D, SEMA4D
  • C07K 16/2803 - CD101, BCP#4, GR14, V7
  • C07K 16/2803 - CD111, nectin 1, PRR1, PRR-1, poliovirus(-related) receptor 1
  • C07K 16/2803 - CD112, PRR2, PPR-2, poliovirus(-related) receptor 2, PVRL2, PVRL-2, poliovirus receptor-like 2, HVEB, herpesvirus entry protein B, herpesvirus entry mediator B, nectin 2
  • C07K 16/2803 - CD113, CDw113, nectin 3, PRR3, PRR-3, poliovirus(-related) receptor 3, PPR3, PVRR3, PVRL3, PVRL-3, poliovirus receptor-like 3
  • C07K 16/2803 - CD117, c-kit, SCFR, SCF-R, SCF receptor, stem cell factor receptor
  • C07K 16/2803 - CD147, basigin, neurothelin, M6, emmprin, extracellular matrix metalloproteinase, TCSF, tumor collagenase stimulating factor, basoglin
  • C07K 16/2803 - CD150, CDw150, IPO-3, SLAM, surface lymphocyte activation molecule
  • C07K 16/2803 - CD158
  • C07K 16/2803 - CD158a, p58.1, p58.1 KIR, EB6, KIR2DL1
  • C07K 16/2803 - CD158b1, p58.2, p58.2 KIR, GL183, KIR2DL2
  • C07K 16/2803 - CD158b2, p58.3, p58.3 KIR, KIR2DL3
  • C07K 16/2803 - CD158c, KIRX, KIR X, KIR2DS6
  • C07K 16/2803 - CD158d, KIR2DL4
  • C07K 16/2803 - CD158e1, KIR3DL1
  • C07K 16/2803 - CD158e2, KIR3DS1
  • C07K 16/2803 - CD158f, KIR2DL5
  • C07K 16/2803 - CD158g, KIR2DS5
  • C07K 16/2803 - CD158h, p50.1, KIR2DS1
  • C07K 16/2803 - CD158i, p50.3, KIR2DS4
  • C07K 16/2803 - CD158j, p50.2, KIR2DS2
  • C07K 16/2803 - CD158k, p140, KIR3DL2
  • C07K 16/2803 - CD159, CDw159, NKB1, NKB-1, p70, NKG2A
  • C07K 16/2803 - CD160, CDw160, p140, NK1, NK28, BY55
  • C07K 16/2803 - CD166, ALCAM, activated leukocyte cell adhesion molecule, BEN (chicken), DM-GRASP (chicken), KG-CAM, neurolin (zebrafish), SC-1 (chicken)
  • C07K 16/2803 - CD169, Siglec-1, sialic acid-binding Ig-related lectin 1, sialoadhesin
  • C07K 16/2803 - CD170, Siglec-5, CD33-like 2, sialic acid-binding Ig-related lectin 5, OB-BP2
  • C07K 16/2803 - CD171, L1
  • C07K 16/2803 - CD172, SIRPs, signal regulatory proteins
  • C07K 16/2803 - CD172b, SIRPB1, SIRP beta-1, signal-regulatory protein beta 1, SIRP-B1
  • C07K 16/2803 - CD172g, SIRPB2, SIRP beta-2, signal-regulatory protein beta 2, SIRP gamma, SIRP-B2
  • C07K 16/2803 - CD179
  • C07K 16/2803 - CD179a, IG1, immunoglobulin iota chain (or polypeptide), Vpre-B, VPREB1, VPREB-1, pre-B lymphocyte gene 1
  • C07K 16/2803 - CD179b, IGL5, immunoglobulin omega chain (or polypeptide), IGLL1, IGLL-1, immunoglobulin lambda-like polypeptide, 14.1, lambda 5
  • C07K 16/2803 - CD200, MRC OX2, OX2 (rat), OX-2 (rat)
  • C07K 16/2803 - CD223, LAG-3, lymphocyte activation gene 3
  • C07K 16/2803 - CD226, DNAM1, DNAM-1, DNAX accesory molecule 1, PTA1, PTA-1, platelet and T cell activation antigen 1, TLISA, T lineage-specific activation antigen 1
  • C07K 16/2803 - CD229, Ly9, Ly-9
  • C07K 16/2803 - CD244, 2B4
  • C07K 16/2803 - CD244, 2B4
  • C07K 16/2803 - CD300, CLM
  • C07K 16/2803 - CD300a, CD300LA, CD300 (molecule)-like family member A, CMRF35H, CMRF-35H, CMRF35H9, CMRF-35-H9, IRC1, IRC2, Irp60, IgSF12, CLM8, CLM-8, CMRF35-like molecule 8
  • C07K 16/2803 - CD300b, CD300LB, CD300 (molecule)-like family member B, IREM3, IREM-3, immune receptor expressed by myeloid cells 3, CLM7, CLM-7, CMRF35-like molecule 7, TREM5, TREM-5, triggering receptor expressed on myeloid cells 5
  • C07K 16/2803 - CD300c, CD300LC, CD300 (molecule)-like family member C, CLM6, CLM-6, CMRF35-like molecule 6, CMRF35A, CMRF-35A, LIR, IgSF16, immunoglobulin superfamily member 16, CMRF-35A1,CMRF35, CMRF-35
  • C07K 16/2803 - CD300e, CD300LE, CD300 (molecule)-like family member E, IREM2, IREM-2, immune receptor expressed by myeloid cells, CLM2, CLM-2, CMRF35-like molecule 2, PIgR2, poly-Ig receptor 2
  • C07K 16/2803 - CD300f, CD300LF, CD300 (molecule)-like family member F, IREM1, IREM-1, immune receptor expressed by myeloid cells 1, CLM1, CLM-1, CMRF35-like molecule 1, IgSF13, immunoglobulin superfamily member 13, MAIR-5, MAIR-V, myeloid-associated immunoglobulin-like receptor 5, leukocyte mono-Ig-like receptor 3
  • C07K 16/2803 - CD300g, CD300LG, CD300 (molecule)-like family member G, CLM9, CLM-9, CMRF35-like molecule 9, TREM4, TREM-4, triggering receptor expressed on myeloid cells 4, NEPMUCIN
  • C07K 16/2803 - CD305, LAIR1, LAIR-1, leukocyte-associated Ig-like receptor 1
  • C07K 16/2803 - CD306, LAIR2, LAIR-2, leukocyte-associated Ig-like receptor 2
  • C07K 16/2803 - CD315, CD9 partner 1, CD9P1, PTGFRN, prostaglandin F2 receptor negative regulator, FPRP, EWI-F, SMAP-6, FLJ11001, KIAA1436
  • C07K 16/2803 - CD316, EWI2, IgSF8, immunoglobulin superfamily member 8, PGRL, CD81P3, CD81 partner 3, KASP
  • C07K 16/2803 - CD319, SLAMF7, CRACC, SLAM family member 7, 19A, CS1, 19A24, CD2-like receptor activating cytotoxic cells, CD2 subset 1, LY9-like protein, FOAP-12, Ly9
  • C07K 16/2803 - CD321, JAM1, JAM-1, F11R, F11 receptor, KAT, JCAM, PAM-1, platelet adhesion molecule 1, junctional adhesion molecule 1
  • C07K 16/2803 - CD322, JAM2, JAM-2, VEJAM, PRO245, VE-JAM, vascular endothelial junction-associated molecule, junctional adhesion molecule 2
  • C07K 16/2803 - CD323, JAM3, JAM-3, junctional adhesion molecule 3
  • C07K 16/2803 - CD335, NKp46, NCR1, NCR-1, natural cytotoxicity triggering receptor 1, LY94, NK-p46, Ly-94 homolog
  • C07K 16/2803 - CD336, NKp44, NCR2, NCR-2, natural cytotoxicity triggering receptor 2, LY95, NK-p44, Ly-95 homolog
  • C07K 16/2803 - CD337, NKp30, NCR3, NCR-3, natural cytotoxicity triggering receptor 3, LY117, 1C7, NL-p30
  • C07K 16/2803 - CD352, SLAMF6, NTB-A, KAL.1, Ly108
  • C07K 16/2803 - CD353, SLAMF8, BLAME
  • C07K 16/2803 - CD354, TREM1, TREM-1, triggering receptor expressed in myeloid cells 1
  • C07K 16/2803 - A33, GPA33
  • C07K 16/2803 - A33-like 3
  • C07K 16/2803 - AMIGO-2, amphoterin-induced protein 2
  • C07K 16/2803 - BTF, butyrophilin, BTN
  • C07K 16/2803 - BTN2A1
  • C07K 16/2803 - BTN2A2
  • C07K 16/2803 - BTN2A3
  • C07K 16/2803 - CADM-2, cell adhesion molecule 2
  • C07K 16/2803 - CADM-3, cell adhesion molecule 3
  • C07K 16/2803 - CADM-4, cell adhesion molecule 4
  • C07K 16/2803 - CAR, Coxsackie adenovirus receptor
  • C07K 16/2803 - C-CAM
  • C07K 16/2803 - CD200R, CD200 receptor, OX-2R
  • C07K 16/2803 - CD200Ra, OX-2Ra
  • C07K 16/2803 - CD200Rb, OX-2Rb
  • C07K 16/2803 - CDO, cam-related gene down regulated by oncogenes
  • C07K 16/2803 - contactin, neuro-1 antigen
  • C07K 16/2803 - CTXL, cortical thymocyte receptor-like protein
  • C07K 16/2803 - CXADR, Coxsackie and adenovirus receptor
  • C07K 16/2803 - DCC, deleted in colorectal carcinoma
  • C07K 16/2803 - EndoCAM, gp130
  • C07K 16/2803 - gp49B1
  • C07K 16/2803 - gpVI, glycoprotein VI, TANGO 268
  • C07K 16/2803 - human LIG-1 homolog (HLIG-1)
  • C07K 16/2803 - IgSF4, immunoglobulin superfamily member 4, LDCAM, TSLC1, nectin-like 2, SynCAM, CADM-1, cell adhesion molecule 1
  • C07K 16/2803 - IgSF9, immunoglobulin superfamily member 9
  • C07K 16/2803 - JAM, juctional adhesion molecule
  • C07K 16/2803 - JAM-A
  • C07K 16/2803 - JAM-B
  • C07K 16/2803 - JAM-C
  • C07K 16/2803 - JAML, JAM-L, JAM-like
  • C07K 16/2803 - KIM-1, kidney injury molecule 1, TIM-1, HAVCR-1, hepatitis A virus cellular receptor
  • C07K 16/2803 - KIRHy, killer cell Ig-like receptor-like protein(s)
  • C07K 16/2803 - KIRREL, gp202, nephrin-like protein
  • C07K 16/2803 - LINGO-1, LRRN6, LRRN6A, FLJ14594, LERN1, MGC17422, UNQ201, Sp35
  • C07K 16/2803 - LIR-6A, LIR-PBM36-4
  • C07K 16/2803 - LIR-6B, LIR-PBM36-2
  • C07K 16/2803 - LILRB, PirB
  • C07K 16/2803 - Lisch-like
  • C07K 16/2803 - MadCAM-1, mucosal vascular addressin, mucosal addressin cell adhesion molecule
  • C07K 16/2803 - OMgp, oligodendrocyte myelin glycoprotein, MOgp, myelin oligodendrocyte glycoprotein
  • C07K 16/2803 - OB-CAM, opioid binding cell adhesion molecule
  • C07K 16/2803 - Oscar, osteoclast-associated receptor
  • C07K 16/2803 - PILRalpha, PILR alpha, FDF03
  • C07K 16/2803 - PILRbeta, PILR beta
  • C07K 16/2803 - RAGE, receptor for advanced glycated endproducts
  • C07K 16/2803 - ROBO1, roundabout homolog 1, Slit2 receptor, DUTT1
  • C07K 16/2803 - ROBO2, roundabout homolog 2
  • C07K 16/2803 - ROBO3, roundabout homolog 3
  • C07K 16/2803 - ROBO4, roundabout homolog 4, axon guidance receptor (homolog) 4, ECSM4, magic roundabout, magic robo, MRB
  • C07K 16/2803 - ROR-1, ROR1, receptor tyrosine kinase orphan receptor 1
  • C07K 16/2803 - ROR-2, ROR2, receptor tyrosine kinase orphan receptor 2
  • C07K 16/2803 - siglec, sialic acid-binding Ig-related lectin
  • C07K 16/2803 - siglec-4, sialic acid-binding Ig-related lectin 4, MAG, myelin-associated glycoprotein
  • C07K 16/2803 - siglec -4b, sialic acid-binding Ig-related lectin 4b, SMP, Schwann cell myelin protein
  • C07K 16/2803 - siglec-6, sialic acid-binding Ig-related lectin 6, OB-BP1, CD33L
  • C07K 16/2803 - siglec-7, sialic acid-binding Ig-related lectin 7
  • C07K 16/2803 - siglec-8, sialic acid-binding Ig-related lectin 8
  • C07K 16/2803 - siglec-9, sialic acid-binding Ig-related lectin 9
  • C07K 16/2803 - siglec-10, sialic acid-binding Ig-related lectin 10
  • C07K 16/2803 - siglec-11, sialic acid-binding Ig-related lectin 11
  • C07K 16/2803 - siglec-12, sialic acid-binding Ig-related lectin 12
  • C07K 16/2803 - siglec-13, sialic acid-binding Ig-related lectin 13
  • C07K 16/2803 - siglec-14, sialic acid-binding Ig-related lectin 14
  • C07K 16/2803 - siglec-15, sialic acid-binding Ig-related lectin 15
  • C07K 16/2803 - SPEX, spleen expressed protein
  • C07K 16/2803 - TARM, T cell interacting receptor on myeloid cells
  • C07K 16/2803 - TIM-3, T cell immunoglobulin and mucin domain 3
  • C07K 16/2803 - TOSO, PIGRL
  • C07K 16/2803 - TREM1, TREM-1, triggering receptor expressed in myleoid cells 1
  • C07K 16/2803 - TREM2, TREM-2, triggering receptor expressed in myeloid cells 2
  • C07K 16/2803 - TREM3, TREM-3, triggering receptor expressed in myeloid cells 3
  • C07K 16/2803 - TREM4, TREM-4, triggering receptor expressed in myeloid cells 4
  • C07K 16/2803 - TREM11, TREM-11, triggering receptor expressed in myeloid cells 11
  • C07K 16/2803 - TREML1, TREML-1, TLT1, TLT-1, TREM like 1
  • C07K 16/2803 - TREML2, TREML-2, TLT2, TLT-2, TREM like 2
  • C07K 16/2803 - TREML3, TREML-3, TLT3, TLT-3, TREM like 3
  • C07K 16/2803 - TREML4, TREML-4, TLT4, TLT-4, TREM like 4
  • C07K 16/2803 - UncB5, Unc-5 homolog B, netrin receptor
  • C07K 16/2803 - vaccinia virus B15 receptor
  • C07K 16/2806 - CD2, E-rosette receptor, LFA-2, lymphocyte function antigen 2, SRBC receptor, sheep red blood cell receptor, T11
  • C07K 16/2806 - CD2R, T11-3
  • C07K 16/2809 - CD3, TcR, CD3-TcR complex, TcR-CD3 complex, Ti, T3, Leu4, Leu-4
  • C07K 16/2809 - CD247, zeta chain, CD3 zeta chain
  • C07K 16/2812 - CD4, T4, Leu3, Leu-3, L3T4 (mouse), W3/25 (rat)
  • C07K 16/2818 - CD28, T44, Tp44
  • C07K 16/2818 - CD152, CTLA4, CTLA-4
  • C07K 16/2818 - CD272, BTLA, B and T lymphocyte attenuator, B and T lymphocyte associated
  • C07K 16/2818 - CD278, ICOS, inducible costimulator, AILIM, inducible T cell co-stimulator, MGC39850, CRP-1, CD28-related protein 1, CLP, CTLA-4-like protein
  • C07K 16/2818 - CD279, PD-1, programmed death 1, PDCD1, programmed (cell) death 1, SLEB2, hPD-1
  • C07K 16/2818 - Tim-3
  • C07K 16/2818 - zB7R1
  • C07K 16/283 - CD16, Fc gamma receptor III, FcgammaRIII, low affinity receptor for monomeric IgG, low affinity Fcgamma receptor, Leu11, Leu-11
  • C07K 16/283 - CD16a, FcgammaRIIIA, Fcgamma RIIIA, Fc gamma receptor IIIA
  • C07K 16/283 - CD16b, FcgammaRIIIB, Fcgamma RIIIB, Fc gamma receptor IIIB
  • C07K 16/283 - CD32, Fc gamma receptor II, FcgammaRII, low affinity receptor for aggregated IgG, Fcgamma RII
  • C07K 16/283 - CD32A, Fcgamma receptor IIA, FcgammaRIIa, Fcgamma RIIA
  • C07K 16/283 - CD32B, Fc gamma receptor IIB, FcgammaRIIb, Fcgamma RIIB
  • C07K 16/283 - CD32C, Fc gamma receptor IIC, FcgammaRIIc, Fcgamma RIIC
  • C07K 16/283 - CD64, Fc gamma receptor I, FcgammaRI, high affinity receptor for IgG, high affinity Fcgamma receptor
  • C07K 16/283 - CD89, FcalphaR, IgA receptor, receptor for IgA
  • C07K 16/283 - CD307, IRTA2, immunoglobulin superfamily receptor translocation associated 2, BXMAS1, FLJ00333, RP11-217A12.1, FcRH5, FcRH-5, IRTA-2
  • C07K 16/283 - FcepsilonRI, Fc epsilon receptor I, FCEH receptor, high affinity receptor for IgE
  • C07K 16/283 - IRTA1, IRTA-1, immune receptor translocation-associated 1, Fc receptor homolog 1, FcRH-4, immunoglobulin superfamily receptor translocation associated 1, FcRH4
  • C07K 16/283 - IRTA3, IRTA-3, immune receptor translocation-associated 3, Fc receptor homolog 3, FcRH-3, immunoglobulin superfamily receptor translocation associated 3, FcRH3
  • C07K 16/283 - IRTA4, IRTA-4, immune receptor translocation-associated 4, Fc receptor homolog 4, FcRH-2, immunoglobulin superfamily receptor translocation associated 4, FcRH2
  • C07K 16/283 - IRTA5, IRTA-5, immune receptor translocation-associated 5, Fc receptor homolog 5, FcRH-1, immunoglobulin superfamily receptor translocation associated 5, FcRH1
  • C07K 16/283 - IRTA6, IRTA-6, immune receptor translocation-associated 6, Fc receptor homolog 6, FcRH-6, immunoglobulin superfamily receptor translocation associated 6, FcRH6
  • C07K 16/283 - pIgR, poly-Ig receptor
  • C07K 16/2842 - integrin beta1 (subunit-)containing molecule(s)
  • C07K 16/2842 - CD49a, CD49a/CD29, VLA-1, very late antigen 1, integrin alpha1beta1
  • C07K 16/2842 - CD49b, CD49b/CD29, VLA-2, very late antigen 2, ECMRII, ECMR-II, extracellular matrix receptor (type) II, (platelet) gpIa, (platelet) gpIa/IIa, integrin alpha2beta1
  • C07K 16/2842 - CD49c, CD49c/CD29, VLA-3, very late antigen 3, ECMRI, ECMR-I, extracellular matrix receptor (type) I, integrin alpha3beta1
  • C07K 16/2842 - CD49d, CD49d/CD29, VLA-4, very late antigen 4, integrin alpha4beta1
  • C07K 16/2842 - CD49e, CD49e/CD29, VLA-5, very late antigen 5, ECMRVI, ECMR-VI, extracellular matrix receptor (type) VI, (platelet) gpIc, (platelet) gpIc/IIa, integrin alpha5beta1, fibronectin receptor alpha chain
  • C07K 16/2842 - CD49f, CD49f/CD29, VLA-6, very late antigen 6, integrin alpha6beta1
  • C07K 16/2842 - LPAM-2, lymphocyte Peyer's patch adhesion molecule 2
  • C07K 16/2848 - integrin beta3 (subunit-)containing molecule(s)
  • C07K 16/2848 - CD41, CD41/CD61, (platelet) gpIIb, (platelet) gpIIb/gpIIIa, (platelet) GpIIb/IIIa
  • C07K 16/2848 - CD51, CD51/CD61 VNR, VN-R, vitronectin receptor
  • C07K 16/2848 - CD61, CD41/CD61, CD51/CD61, (platelet) gpIIIa, (platelet) gpIIb/IIIa
  • C07K 16/2854 - selectins
  • C07K 16/2854 - CD62, selectin
  • C07K 16/2854 - CD62E, E-selectin, ELAM-1, endothelial leukocyte adhesion molecule 1, LECAM-2, LEC-CAM-2
  • C07K 16/2854 - CD62L, L-selectin, LAM-1, Leu8, Leu-8, LECAM-1, LEC-CAM-1, TQ1, TQ-1, MEL-14, DREG, peripheral lymph node homing receptor, pnHR, gp100MEL, gp110MEL
  • C07K 16/2854 - CD62P, P-selectin, LECAM-3, LEC-CAM-3, PADGEM, gmp140, GMP-140, platelet activation dependent granule external membrane
  • C07K 16/2866 - chemokine en cytokine receptors
  • C07K 16/2866 - CD25, Tac, IL-2R, IL-2Ralpha, IL-2R alpha (chain), IL-2 receptor alpha (chain), interleukin-2 receptor alpha (chain), TCGFR, TCGF-R, TCGF receptor, T cell growth factor receptor
  • C07K 16/2866 - CD110, MPL, TPOR, TPO-R, TPO receptor, thrombopoietin receptor
  • C07K 16/2866 - CD114, G-CSFR, G-CSF-R, G-CSF receptor, granulocyte colony-stimulating factor receptor, CSF3R, CSF-3R
  • C07K 16/2866 - CD115, M-CSFR, M-CSF-R, M-CSF receptor, macrophage colony-stimulating factor receptor, CSF1R, CSF-1R, c-fms
  • C07K 16/2866 - CD116, GM-CSFR, GM-CSF-R, GM-CSF receptor, granulocyte macrophage colony-simulating factor receptor
  • C07K 16/2866 - CD118, LIFR, leukemia inhibitory factor receptor
  • C07K 16/2866 - CD119, CDw119, IFNgR, IFN-gamma receptor, interferon gamma receptor, IFNGR
  • C07K 16/2866 - CD121a, IL-1R type 1, IL-1 receptor type 1, interleukin-1 receptor type 1
  • C07K 16/2866 - CD121b, IL-1R type 2, IL-1 receptor type 2, interleukin-1 receptor type 2
  • C07K 16/2866 - CD122, IL-2Rbeta, IL-2R beta (chain), IL-2 receptor beta (chain), interleukin-2 receptor beta (chain)
  • C07K 16/2866 - CD123, IL-3Ralpha, IL-3R alpha (chain), IL-3 receptor alpha (chain), interleukin-3 receptor alpha (chain), CDw123
  • C07K 16/2866 - CD124, IL-4R, IL-4 receptor, interleukin-4 receptor
  • C07K 16/2866 - CD125, CDw125, IL-5Ralpha, IL-5R alpha (chain), IL-5 receptor alpha (chain), interleukin-5 receptor alpha (chain)
  • C07K 16/2866 - CD126, IL-6R, IL-6 receptor, interleukin-6 receptor
  • C07K 16/2866 - CD127, IL-7R, IL-7 receptor, interleukin-7 receptor, IL-7Ralpha, IL-7R alpha (chain), IL-7 receptor alpha (chain), interleukin-7 receptor alpha (chain)
  • C07K 16/2866 - CDw128
  • C07K 16/2866 - CD129, IL-9R, IL-9 receptor, interleukin-9 receptor
  • C07K 16/2866 - CD130, gp130
  • C07K 16/2866 - CD131, CDw131, common beta chain, common cytokine receptor beta chain
  • C07K 16/2866 - CD132, common gamma chain, common cytokine receptor gamma chain
  • C07K 16/2866 - CD181, CD128a, CDw128a, CXCR1, chemokine (type) CXC receptor 1, IL-8RA, IL-8Ralpha, IL-8 receptor A, interleukin-8 receptor A, interleukin-8 receptor alpha
  • C07K 16/2866 - CD182, CD128b, CDw128b, CXCR2, chemokine (type) CXC receptor 2, IL-8RB, IL-8Rbeta, IL-8 receptor B, interleukin-8 receptor B, interleukin-8 receptor beta
  • C07K 16/2866 - CD183, CXCR3, chemokine (type) CXC receptor 3
  • C07K 16/2866 - CD184, CXCR4, chemokine (type) CXC receptor 4, fusin, HUMSTR, LESTR
  • C07K 16/2866 - CD185, CXCR5, chemokine (type) CXC receptor 5, BLR1, BLR-1, Burkitt lymphoma receptor 1, MDR15
  • C07K 16/2866 - CD186, CDw186, CXCR6, chemokine (type) CXC receptor 6, BONZO, STRL33, TYMSTR
  • C07K 16/2866 - CD191, CCR1, chemokine (type) CC receptor 1, CKR-1, CC-CKR1, CMKBR1
  • C07K 16/2866 - CD192, CCR2, chemokine (type) CC receptor 2, CKR-2, CC-CKR2, MPC-1-R, MCP-1R, MCP-1 receptor, CCR2A, CCR2B, CKR2A, CKR2B, CMKBR2
  • C07K 16/2866 - CD193, CCR3, chemokine (type) CC receptor 3, CKR-3, CC-CKR3, CMKBR3
  • C07K 16/2866 - CD194, CCR4, chemokine (type) CC receptor 4, CKR-4, CC-CKR4, CMKBR4
  • C07K 16/2866 - CD195, CCR5, chemokine (type) CC receptor 5, CKR-5, CC-CKR5, CMKBR5
  • C07K 16/2866 - CD196, CCR6, chemokine (type) CC receptor 6, CKR-6, CC-CKR6, CMKBR6, BN-1, DCR2, CKRL3, DRY-6, GPR29, GPRCY4, GPR-CY4, STRL22, CKR-L3, LARC receptor
  • C07K 16/2866 - CD197, CDw197, CCR7, chemokine (type) CC receptor 7, CKR-7, CC-CKR7, CMBKR7
  • C07K 16/2866 - CD197, CDw197, CCR7, chemokine (type) CC receptor 7, CKR-7, CC-CKR7, CMBKR7
  • C07K 16/2866 - CD198, CDw198, CCR8, chemokine (type) CC receptor 8, CKR-8, CC-CKR8, CMBKR8, CY6, TER1, CKRL1, CKR-L1, GPR-CY6, CMKBRL2
  • C07K 16/2866 - CD199, CDw199, CCR9, chemokine (type) CC receptor 9, CKR-9, CC-CKR9, CMBKR9, GPR28, GPR-9-6
  • C07K 16/2866 - CD210, CDw210, IL-10R, IL-10 receptor, interleukin-10 receptor
  • C07K 16/2866 - CD212, IL-12Rbeta1, IL-12 receptor beta 1, interleukin-12 receptor beta 1
  • C07K 16/2866 - CD213a1, IL-13R alpha 1, interleukin-13 receptor alpha 1
  • C07K 16/2866 - CD213a2, IL-13R alpha 2, interleukin-13 receptor alpha 2
  • C07K 16/2866 - CD217, IL-17R, IL-17 receptor, interleukin-17 receptor, zcytor14
  • C07K 16/2866 - CD218a, CDw218A, IL-18RA, IL-18R alpha, interleukin-18 receptor 1, interleukin-18 receptor alpha, IL1RRP, IL-1Rrp
  • C07K 16/2866 - CD218b, CDw218B, IL-18RB, IL-18R beta, interleukin-18 receptor beta, interleukin-18 receptor accessory protein, ACPL, IL18RAP
  • C07K 16/2866 - chemerinR, chemerin receptor, dez, CMKLR1, CMKLR-1, chemokine-like receptor 1
  • C07K 16/2866 - EphA1, ephrin receptor A1
  • C07K 16/2866 - EphA2, ephrin receptor A2
  • C07K 16/2866 - EphA3a, ephrin receptor A3a
  • C07K 16/2866 - EphA3b, ephrin receptor A3b
  • C07K 16/2866 - EphA4, ephrin receptor A4
  • C07K 16/2866 - EphA5a, ephrin receptor A5a
  • C07K 16/2866 - EphA5b, ephrin receptor A5b
  • C07K 16/2866 - EphA6, ephrin receptor A6
  • C07K 16/2866 - EphA7, ephrin receptor A7
  • C07K 16/2866 - EphA8, ephrin receptor A8
  • C07K 16/2866 - EphA9, ephrin receptor A9,
  • C07K 16/2866 - EphA10, ephrin receptor A10
  • C07K 16/2866 - EphB1, ephrin receptor B1, Elk, Cek6, Net, Hek6
  • C07K 16/2866 - EphB2, ephrin receptor 2, Cek5, Nuk, Erk, Qek5, Tyro5, Sek3, Hek5, Drt
  • C07K 16/2866 - EphB2a, ephrin receptor B2a
  • C07K 16/2866 - EphB2b, ephrin receptor B2b
  • C07K 16/2866 - EphB3, ephrin receptor B3, Cek10, Hek2, Mdk5, Tyro6, Sek4, Hek4, Mek4
  • C07K 16/2866 - EphB4, ephrin receptor B4, Htk, Myk1, Mdk2, Tyro11, hepatoma transmembrane kinase (also in C07K 16/30)
  • C07K 16/2866 - EphB5, ephrin receptor B5, Cek9, Hek9
  • C07K 16/2866 - EphB6, ephrin receptor B6, Mep
  • C07K 16/2866 - Hek7, Cek7
  • C07K 16/2866 - Hek8, Cek8
  • C07K 16/2866 - Hek11
  • C07K 16/2866 - IFNAR, interferon alpha receptor
  • C07K 16/2866 - IFNAR-1, interferon alpha receptor 1
  • C07K 16/2866 - IFNAR-2, interferon alpha receptor 2
  • C07K 16/2866 - IL-1RAP, IL1RAP, IL-1RAcP, IL1R3, c3orf13, Il-1 receptor accessory protein
  • C07K 16/2866 - IL-11R, IL-11 receptor, interleukin-11 receptor
  • C07K 16/2866 - IL-14R, IL-14 receptor, interleukin-14 receptor
  • C07K 16/2866 - IL-15R, IL-15 receptor, interleukin-15 receptor
  • C07K 16/2866 - IL-16R, IL-16 receptor, interleukin-16 receptor
  • C07K 16/2866 - IL-17FR, IL-17F receptor
  • C07K 16/2866 - IL-17R, IL-17 receptor, interleukin-17 receptor, IL-17RA, IL-17 receptor A, interleukin-17 receptor A
  • C07K 16/2866 - IL-17RB, IL-17 receptor B, interleukin-17 receptor B
  • C07K 16/2866 - IL-17RC, IL-17 receptor C, interleukin-17 receptor C
  • C07K 16/2866 - IL-17RD, IL-17 receptor D, interleukin-17 receptor D
  • C07K 16/2866 - IL-17RE, IL-17 receptor E, interleukin-17 receptor E
  • C07K 16/2866 - IL-17RF, IL-17 receptor F, interleukin-17 receptor F
  • C07K 16/2866 - IL-19R, IL-19 receptor, interleukin-19 receptor
  • C07K 16/2866 - IL-20R, IL-20 receptor, interleukin-20 receptor
  • C07K 16/2866 - IL-21R, IL-21 receptor, interleukin-20 receptor, MU-1
  • C07K 16/2866 - IL-22RA, IL-22 receptor alpha, interleukin-22 receptor alpha, zcytor11
  • C07K 16/2866 - IL-23R, IL-23 receptor, interleukin-23 receptor, DCRS5, DNAX cytokine receptor subunit 5
  • C07K 16/2866 - IL-27R, IL-27 receptor, interleukin-27 receptor, TCCR
  • C07K 16/2866 - IL-27RA, WXS-1, IL-27 receptor alpha, interleukin 27 receptor alpha
  • C07K 16/2866 - IL-28R, IL-28 receptor, interleukin-28 receptor
  • C07K 16/2866 - IL-31RA, IL-31 receptor A, NR10, cytokine receptor nr. 10, CRL, CRL3, GLM-R, GPL, MGC125346, PRO21384, cytokine receptor-like 3, WAP5, whey acidic protein 5
  • C07K 16/2866 - IL-33R, IL-33 receptor, interleukin-33 receptor, ILRL1, ST2, T1/ST2, Fit-1, DER4, DER-4
  • C07K 16/2866 - L-CCR, LPS-inducible CC chemokine receptor
  • C07K 16/2866 - TPOR, TPO-R, TPO receptor, thrombopoietin receptor, Mp1
  • C07K 16/2866 - WSX receptor
  • C07K 16/2866 - zalpha11
  • C07K 16/2869 - hormone receptors
  • C07K 16/2869 - CD220, insulin receptor
  • C07K 16/2869 - CD295, LEPR, leptin receptor
  • C07K 16/2869 - Adrenoreceptors, adrenergic receptors, adrenoceptors, epinephrine receptors, adrenaline receptors, norepinephrine receptors, noradrenaline receptors (also in C07K 16/286)
  • C07K 16/2869 - Alarin receptor
  • C07K 16/2869 - Alpha-1 adrenoreceptor, alpha-1 adrenergic receptor, alpha-1 adrenoceptor, A1AR, alpha-1 AR, ADRA1R, ALPHA1AR (also in C07K 16/286)
  • C07K 16/2869 - Alpha-2 adrenoreceptor, alpha-2 adrenergic receptor, alpha-2 adrenoceptor, A2AR, alpha-2 AR, ADRA2R, ALPHA2AR (also in C07K 16/286)
  • C07K 16/2869 - Androgen receptor, AR
  • C07K 16/2869 - Angiotensin-II type-1 receptor, AT1
  • C07K 16/2869 - Angiotensin-II type-2 receptor, AT2
  • C07K 16/2869 - Anti-Müllerian hormone type II receptor, AMH type II receptor, AMH receptor type II, AMHIIR, AMHRII, MISIIR, MISRII, MIFIIR, MIFRII, AMHR-II, AMH-RII, MISR-II, MIS-RII, MIFR-II, MIF-RII
  • C07K 16/2869 - Apelin receptor, AGTRIA, APJ
  • C07K 16/2869 - Apelin receptor
  • C07K 16/2869 - Atrial natriuretic factor complex
  • C07K 16/2869 - Atriopeptin receptor
  • C07K 16/2869 - Atrial natriuretic peptide receptor, ANP receptor
  • C07K 16/2869 - Beta-1 adrenoreceptor, beta-1 adrenergic receptor, beta-1 adrenoceptor, B1AR, beta-1 AR, ADRB1R, BETA1AR, RHR (also in C07K 16/286)
  • C07K 16/2869 - Beta-2 adrenoreceptor, beta-2 adrenergic receptor, beta-2 adrenoceptor, B2AR, beta-2 AR, ADRB2R, BETA2AR (also in C07K 16/286)
  • C07K 16/2869 - Bombesin receptor
  • C07K 16/2869 - Calcitonin receptor
  • C07K 16/2869 - Calcitonin gene-related peptide receptor
  • C07K 16/2869 - Cardionatrin receptor
  • C07K 16/2869 - Cardiodilatin receptor
  • C07K 16/2869 - Cholecystokinin receptor, CCK receptor
  • C07K 16/2869 - Chorionic gonadotropin receptor, HCG receptor
  • C07K 16/2869 - Chorionic somatomammotropin receptor
  • C07K 16/2869 - Corticotropin receptor
  • C07K 16/2869 - Corticotropin releasing factor receptor, CRF receptor, urotensin receptor
  • C07K 16/2869 - CRF1R, corticotropin-releasing factor 1 receptor
  • C07K 16/2869 - CRF2R, corticotropin-releasing factor 2 receptor
  • C07K 16/2869 - Endorphin receptor
  • C07K 16/2869 - Endothelin receptor
  • C07K 16/2869 - Enkephalin receptor
  • C07K 16/2869 - Follicle-stimulating hormone receptor, FSH receptor
  • C07K 16/2869 - Galanin receptor, GAL receptor
  • C07K 16/2869 - Galanin-like peptide receptor, GALP receptor
  • C07K 16/2869 - Gastrin receptor
  • C07K 16/2869 - Gastrin releasing peptide receptor
  • C07K 16/2869 - Ghrelin receptor
  • C07K 16/2869 - GIP receptor, gastric inhibitory polypeptide receptor
  • C07K 16/2869 - Glucagon receptor
  • C07K 16/2869 - GLP-1 receptor, glucagon-like peptide 1 receptor, GLP1R, GLP-1R
  • C07K 16/2869 - GLP-2 receptor, glucagon-like peptide 2 receptor, GLP2R, GLP-2R
  • C07K 16/2869 - Growth hormone receptor, GH receptor, somatotropin receptor
  • C07K 16/2869 - Growth hormone releasing factor receptor, GHRF receptor
  • C07K 16/2869 - Lipotropin receptor
  • C07K 16/2869 - Luteinising hormone receptor, LH receptor
  • C07K 16/2869 - Melanocortin 1 receptor, MC1R, MCR1
  • C07K 16/2869 - Melanocortin 2 receptor, MC2R, MCR2
  • C07K 16/2869 - Melanocortin 3 receptor, MC3R, MCR3
  • C07K 16/2869 - Melanocortin 4 receptor, MC4R, MCR4
  • C07K 16/2869 - Melanocortin 5 receptor, MC5R, MCR5
  • C07K 16/2869 - Melanocyte stimulating hormone receptor, MSH receptor
  • C07K 16/2869 - Melanotropin receptor
  • C07K 16/2869 - Motilin receptor
  • C07K 16/2869 - Orphan glycoprotein hormone receptor, OGH receptor
  • C07K 16/2869 - Parathyroid hormone receptor, parathormone receptor
  • C07K 16/2869 - Parathyroid hormone related peptide receptor
  • C07K 16/2869 - Prolactin receptor
  • C07K 16/2869 - Prostaglandin receptors
  • C07K 16/2869 - Prostaglandin E2 receptor, PGE2 receptor, PGE2R
  • C07K 16/2869 - Relaxin receptor
  • C07K 16/2869 - Salusin alpha receptor
  • C07K 16/2869 - Salusin beta receptor
  • C07K 16/2869 - Secretin receptor
  • C07K 16/2869 - Serotonin receptor
  • C07K 16/2869 - Somatostatin receptor
  • C07K 16/2869 - Substance P receptor
  • C07K 16/2869 - TFF3 receptor
  • C07K 16/2869 - Thymopoietin receptor
  • C07K 16/2869 - Thymosin receptor
  • C07K 16/2869 - Thyroid stimulating hormone receptor, TSH receptor
  • C07K 16/2869 - Vasoactive intestinal contractor receptor, VIC receptor
  • C07K 16/2869 - Vasoactive intestinal peptide receptor 1, VIP receptor, FLJ41949, HVR1 II, PACAP-R-2, RCD1, RDC1, VAPC1, VIP-R1, VIPR, VIRG, VPAC1, VPCAP1R
  • C07K 16/2875 - NGF/TNF (ligand) superfamily
  • C07K 16/2875 - CD70, CD27L, CD27-L, CD27 ligand, Ki-24, TNFSF7, tumor necrosis factor (ligand) superfamily member 7
  • C07K 16/2875 - CD153, CD30L, CD30-L, CD30 ligand, TNFSF8, tumor necrosis factor superfamily member 8
  • C07K 16/2875 - CD154, CD40L, CD40-L, CD40 ligand, CD40CR, gp39, T-BAM, 5c8, TRAP, TNFSF5, tumor necrosis factor (ligand) superfamily member 5, IMD3, HIGM1
  • C07K 16/2875 - CD178, CD95L, CD95-L, CD95 ligand, FasL, Fas-L, Fas ligand, Apo-1L, Apo-1 ligand, APT1LG1, TNFSF6, tumor necrosis factor (ligand) superfamily member 6
  • C07K 16/2875 - CD252, CD134L, CD134-L, CD134 ligand, gp34, OX40L, OX40-L, OX40 ligand, Act-4L, Act-4-L, Act-4 ligand, TXGP1, TNFSF4, TNFSF-4, tumor necrosis factor (ligand) superfamily member 4
  • C07K 16/2875 - CD253, AIM-I, apoptosis-inducing molecule I, AGP-1, Apo-2L, Apo-2 ligand, TL2, TRAIL, TNFSF10, TNFSF-10, tumor necrosis factor (ligand) superfamily member 10, TL-2
  • C07K 16/2875 - CD254, RANKL, RANK-L, RANK ligand, OPGL, OPG-L, OPG ligand, osteoprotegerin ligand, osteoprotegerin binding protein, ODF, sODF, osteoclast differentiation factor, TRANCE, hRANKL2, TNFSF11, TNFSF-11, tumor necrosis factor (ligand) superfamily member 11, receptor activator of NF-kappaB ligand, receptor activator of NF-kB ligand
  • C07K 16/2875 - CD255, Apo-3L, Apo-3 ligand, TRELL, TRAIL-related ligand, TREPA, TNF-related endothelial proliferative agent, TWEAK, T cell ligand weakly inducing apoptosis, DR3L, TNFSF12, tumor necrosis factor (ligand) superfamily member 12
  • C07K 16/2875 - CD256, APRIL, a proliferation-inducing ligand, TNF-related death ligand, TRDL, TRDL-1, TL3, TL-3, TNF ligand 3, TNF gamma, VEGI, vascular endothelial cell growth inhibitor, TALL2, TALL-2, TNFSF13, TNFSF-13, tumor necrosis factor (ligand) superfamily member 13
  • C07K 16/2875 - CD257, BAFF, B cell activation factor, BLyS, TALL1, TALL-1, THANK, ZTNF4, TNFSF20, delta BAFF, TNFSF13B, TNFSF-13B, tumor necrosis factor (ligand) superfamily member 13B, ntn-2, kay-ligand, neutrokine
  • C07K 16/2875 - CD258, LTg, HVEML, LIGHT, TNFSF14, TNFSF-14, tumor necrosis factor (ligand) superfamily member 14, TL5, TL-5
  • C07K 16/2875 - AIM-II, apoptosis-inducing molecule II
  • C07K 16/2875 - EDA,EDA1, ectodysplasin (isoform) A1
  • C07K 16/2875 - EDA2, ectodysplasin (isoform) A2
  • C07K 16/2875 - TL1A, TL-1A, TNFSF15, tumor necrosis factor superfamily member 15
  • C07K 16/2875 - ZTNF13
  • C07K 16/2878 - NGFR/TNFR superfamily, NGF receptor/TNF receptor superfamily
  • C07K 16/2878 - CD27, TNFRSF7, tumor necrosis factor receptor superfamily member 7, Tp55, S152, T14
  • C07K 16/2878 - CD30, Ber-H2, Ki-1, D1S166E, TNFRSF8, tumor necrosis factor receptor superfamily member 8,
  • C07K 16/2878 - CD40, TNFRSF5, tumor necrosis factor receptor superfamily member 5, p50, Bp50
  • C07K 16/2878 - CD40-associated protein, CAP
  • C07K 16/2878 - CD95, Apo-1, Fas, APT1, TNFRSF6, tumor necrosis factor receptor superfamily member 6, apoptosis antigen 1
  • C07K 16/2878 - CD120, TNFR, TNF receptor, tumor necrosis factor receptor
  • C07K 16/2878 - CD120a, 55 kD TNFR, TNFR-1, TNFR-I, TNF receptor 1, TNF receptor I, TNFAR, TNFR60, p55, TNFRSF1A, tumor necrosis factor receptor superfamily member 1A
  • C07K 16/2878 - CD120b, 75 kD TNFR, TNFR-2, TNFR-II, TNF receptor 2, TNF receptor II, TNFBR, TNFR80, p75, TNFRSF1B, tumor necrosis factor receptor superfamily member 1B
  • C07K 16/2878 - CD134, Act-4, OX40, OX-40, Stan-40, ACT35, TXGP1L, TNFRSF4, tumor necrosis factor receptor superfamily member 4
  • C07K 16/2878 - CD137, CDw137, ILA, induced by lymphocyte activation, 4-1BB, TNFRSF9, tumor necrosis factor receptor superfamily member 9
  • C07K 16/2878 - CD260, LTbetaR, lymphotoxin beta receptor, LTbeta receptor, TNFRSF3, TNFRSF-3, tumor necrosis factor receptor superfamily member 3, TNFCR, TNF-R-III, TNFR2-RP
  • C07K 16/2878 - CD261, DR4, death receptor 4, death domain-containing receptor 4, TR1, TRAILR1,TRAIL-R1, TRAIL receptor 1, Apo-2, APO2, apoptosis antigen 2, TNFRSF10a, TNFRSF-10a, tumor necrosis factor receptor superfamily member 10a, MGC9365
  • C07K 16/2878 - CD262, DR5, death receptor 5, death domain-containing receptor 5, TR2 (?), TRAILR2, TRAIL-R2, TRAIL receptor 2, KILLER, TRICK2, TRICKB, ZTNFR9, TNFRSF10b, TNFRSF-10b, tumor necrosis factor receptor superfamily member 10b
  • C07K 16/2878 - CD263, TR5, TNFR-5, TNF receptor 5, TRAILR3, TRAIL-R3, TRAIL receptor 3, TRID, LIT, DCR1, TNFRSF10c, TNFRSF-10c, tumor necrosis factor receptor superfamily member 10c
  • C07K 16/2878 - CD264, TR4, TRAILR4, TRAIL-R4, TRAIL receptor 4, DCR2, TRUNDD, TNFRSF10d, TNFRSF-10d, tumor necrosis factor receptor superfamily member 10d
  • C07K 16/2878 - CD265, RANK, receptor activator of NF-kappaB, ODAR, osteoclast differentiation and activation receptor, TRANCER, TRANCE-R, TRANCE receptor, EOF, FEO, OFE, ODFR, PDB2, TNFRSF11a, TNFRSF-11a, tumor necrosis factor receptor superfamily member11a, osteoclast differentiation factor receptor, receptor activator of NF-kB
  • C07K 16/2878 - CD266, TWEAKR, TWEAK-R, TWEAK receptor, FN14, TNFRSF12a, TNFRSF-12a, tumor necrosis factor receptor superfamily member 12a, FGF-inducible 14
  • C07K 16/2878 - CD267, TACI, transmembrane activator and CAML interactor, TNFRSF13b, TNFRSF-13b, tumor necrosis factor receptor superfamily member 13b
  • C07K 16/2878 - CD268, BAFFR, BAFF-R, BAFF receptor, TNFRSF13c, TNFRSF-13c, tumor necrosis factor receptor superfamily member 13c, TR13c
  • C07K 16/2878 - CD269, BCMA, B cell maturation antigen, TNFRSF17, TNFRSF-17,tumor necrosis factor receptor superfamily 17, TNFRSF13B
  • C07K 16/2878 - CD271, NGFR, NGF-R, NGF receptor, nerve growth factor receptor, p75(NTR), TNFRSF16, TNFRSF-16, tumor necrosis factor receptor superfamily member 16
  • C07K 16/2878 - CD357, AITR, GITR, TNFRSF18, tumor necrosis factor receptor superfamily member 18
  • C07K 16/2878 - CD358, DR6, death (domain(-containing)) receptor 6, TR7, TRAIL-R7, TRAIL receptor 7, TNFRSF21, tumor necrosis factor receptor superfamily member 21
  • C07K 16/2878 - DcR3, TNFRSF6B, tumor necrosis factor receptor superfamily member 6B
  • C07K 16/2878 - DR3, death receptor 3, death domain-containing receptor 3, TR3, TRAIL-R3, TRAIL receptor 3, DDR3, TRAMP, WSL-1, LARD, Apo-3, APO3, apoptosis antigen 3, TNFRSF12, tumor necrosis factor receptor superfamily member 12, TNFRSF25
  • C07K 16/2878 - EDAR, TNFRSF27, EDA1 receptor, ectodysplasin A1 receptor, EDA1R
  • C07K 16/2878 - EDA2R, ectodysplasin A2 receptor, TNFRSF27, tumor necrosis factor receptor superfamily member 27,
  • C07K 16/2878 - XEDAR (?), X-linked EDA1 receptor, X-linked EDAR
  • C07K 16/2878 - FLINT, OPG-3, osteoprotegerin 3
  • C07K 16/2878 - HVEM, herpes simplex virus entry mediator, TR2, ATAR, LIGHTR, LIGHT-R, LIGHT receptor, HveA, TNFRSF14, tumor necrosis factor receptor superfamily member 14
  • C07K 16/2878 - OPG, osteoprotegerin, OCIF, osteoclastogenesis inhibitory factor, TNFRSF11b, tumor necrosis factor receptor superfamily member 11B
  • C07K 16/2878 - TNF-BP-I, tumor necrosis factor binding protein I
  • C07K 16/2878 - TNF-BP-II, tumor necrosis factor binding protein II
  • C07K 16/2878 - TRADD, TNF receptor 1 associated death domain protein
  • C07K 16/2878 - TR6, TRAILR6, TRAIL-R6, TRAIL receptor 6
  • C07K 16/2878 - TR13, TRAILR13, TRAIL-R13, TRAIL receptor 13
  • C07K 16/2878 - TR14, TRAILR14, TRAIL-R14, TRAIL receptor 14
  • C07K 16/2878 - XEDAR
  • C07K 16/2884 - CD44, ECMRIII, ECMR-III, extracellular matrix receptor (type) III, gp85, Hermes, H-CAM, HUTCH-1, pgp-1, phagocytic glycoprotein 1, p85
  • C07K 16/2884 - CD44R, CD44v
  • C07K 16/3007 - CD66e, CEA, carcinoembryonic antigen, CEACAM5, CEACAM-5, carcinoembryonic antigen-related cell adhesion molecule 5
  • C07K 16/3015 - TIMP-2, tissue inhibitor of metalloproteinase 2
  • C07K 16/3053 - MCSP, melanoma chondroitin sulfate proteoglycan, HMW-MAA, high molecular weight melanoma-associated antigen
  • C07K 16/3053 - Melan-A, MART-1
  • C07K 16/36 - CD141, thrombomodulin
  • C07K 16/36 - CD142, blood coagulation factor III, thrombokinin, TF, tissue factor protein, tissue thromboplastin
  • C07K 16/36 - Factor I, blood coagulation factor I, fibrinogen
  • C07K 16/36 - Factor II, blood coagulation factor II, prothrombin
  • C07K 16/36 - Factor III, blood coagulation factor III, tissue thromboplastin
  • C07K 16/36 - Factor IV, blood coagulation factor IV
  • C07K 16/36 - Factor V, blood coagulation factor V, proaccelerin
  • C07K 16/36 - Factor VII, blood coagulation factor VII, proconvertin
  • C07K 16/36 - Factor VIII, blood coagulation factor VIII, antihemophilic factor, AHF, antihemophilic factor A
  • C07K 16/36 - Factor IX, blood coagulation factor IX, antihemophilic factor B, Christmas factor
  • C07K 16/36 - Factor X, blood coagulation factor X, Stuart factor, Stuart-Prower factor
  • C07K 16/36 - Factor XI, blood coagulation factor XI, plasma thromboplastin antecedent, antihemophilic factor C
  • C07K 16/36 - Factor XII, blood coagulation factor XII, Hageman factor
  • C07K 16/36 - Factor XIII, blood coagulation factor XIII, fibrin-stabilizing factor, FSF
  • C07K 16/36 - HMWK, high molecular weight kininogen, HMWK-kallikrein factor, Fitzgerald factor, Williams-Fitzgerald-Flaujeac factor,
  • C07K 16/36 - vWF, von Willebrand's factor
  • C07K 16/40 - enzymes
  • C07K 16/40 - CD10, CALLA, common acute lymphoblastic leukemia antigen, enkephalinase, gp100, NEP, neutral endopeptidase (also in C07K 16/2896)
  • C07K 16/40 - CD13, APN, aminopeptidase N, gp150 (also in C07K 16/2896)
  • C07K 16/40 - CD26, ADA binding protein, DPPIV, DPP IV, dipeptidyl peptidase IV (also in C07K 16/2896)
  • C07K 16/40 - CD143, angiotensin-converting enzyme, carboxycathepsin, dipeptidyl carboxypeptidase, kininase II, peptidyl dipeptidase A (also in C07K 16/2896)
  • C07K 16/40 - CD203c, nucleotide pyrophosphatase/phosphodiesterase 3, phosphodiesterase 1/nucleotide pyrophosphatase 3, NPP3, E-NPP3, B10, gp130RBt3-6, PDNP3, Pdnpno (also in C07K 16/2896)
  • C07K 16/40 - CD224, gamma-glutamyl transferase (also in C07K 16/2896)
  • C07K 16/40 - CD246, anaplastic lymphoma kinase (also in C07K 16/2896)
  • C07K 16/40 - CD249, ENPEP, glutamyl aminopeptidase, aminopeptidase A, APA, gp160 (also in C07K 16/2896)
  • C07K 16/40 - CD296, ART1, ADP-ribosyltransferase 1, RT6 (also in C07K 16/2896)
  • C07K 16/40 - CD297, ART4, Dombrook blood group, DOK1, DO (also in C07K 16/2896)
  • C07K 16/40 - CD298, ATP1B3, ATPase Na+/K+ transporting beta3, ATPB-3, FLJ29027, sodium/potassium-dependent ATPase beta3, sodium/potassium-transporting ATPase beta-3 chain (also in C07K 16/2896)
  • C07K 16/40 - ADAM10 (also in C07K 16/2896)
  • C07K 16/40 - ADAM12, meltrin alpha
  • C07K 16/40 - ADAM19, meltrin beta
  • C07K 16/40 - AKR1C1
  • C07K 16/40 - Cath, cathepsin
  • C07K 16/40 - Cath-D, cathepsin D
  • C07K 16/40 - Ceruloplasnin
  • C07K 16/40 - COX2, COX-2, cyclooxygenase 2, prostaglandin H2 synthase
  • C07K 16/40 - FAP-alpha, fibroblast activating protein alpha, fibroblast activation factor, seprase
  • C07K 16/40 - GPBP, Goodpasture antigen-binding protein
  • C07K 16/40 - HGFA, hepatocyte growth factor activator
  • C07K 16/40 - HtrA, high temperature requirement A
  • C07K 16/40 - HtrA1, high temperature requirement A1
  • C07K 16/40 - HtrA2, high temperature requirement A2, Omi
  • C07K 16/40 - HtrA3, high temperature requirement A3
  • C07K 16/40 - HtrA3-L, high temperature requirement A3 long (isoform)
  • C07K 16/40 - HtrA3-S, high temperature requirement A3 short (isoform)
  • C07K 16/40 - HtrA4, high temperature requirement A4
  • C07K 16/40 - iNOS, inducible nitric oxide synthase, inducible NO synthase
  • C07K 16/40 - Kallikrein
  • C07K 16/40 - LOX, lysyl oxidase
  • C07K 16/40 - LOXL1, LOR-1, lysyloxidase-related protein 1, lysyloxidase-like protein 1
  • C07K 16/40 - LOXL2, LOR-2, lysyloxidase-related protein 2, lysyloxidase-like protein 2
  • C07K 16/40 - LOXL3, LOR-3, lysyloxidase-related protein 3, lysyloxidase-like protein 3
  • C07K 16/40 - LOXL4, LOR-4, lysyloxidase-related protein 4, lysyloxidase-like protein 4
  • C07K 16/40 - MASP1, MASP-1, MBL-associated serine protease 1
  • C07K 16/40 - MASP2, MASP-2, MBL-associated serine protease 2
  • C07K 16/40 - MASP3, MASP-3, MBL-associated serine protease 3
  • C07K 16/40 - Memapsin 2, BACE, BACE1, ASP-2, beta-secretase
  • C07K 16/40 - MN, CA IX, carbonic anhydrase IX, G-250, CA9 (also in C07K 16/30)
  • C07K 16/40 - PCSK9, proprotein convertase subtilisin/kexin type 9, FH3, HCHOLA3, LDLCQ1, NARC-1, NARC1, PC9, PCS9
  • C07K 16/40 - Protein C
  • C07K 16/40 - Pyk-2
  • C07K 16/40 - Seladin-1, selective Alzheimer's disease indicator 1, DHCR24, 24-dehydrocholesterol reductase
  • C07K 16/40 - SLLP1, sperm-specific lysozyme-like protein 1, C19
  • C07K 16/40 - SLLP2, sperm-specific lysozyme-like protein 2, C23
  • C07K 16/40 - SLLP3, sperm-specific lysozyme-like protein 3, C24
  • C07K 16/40 - SLLP4, sperm-specific lysozyme-like protein 4
  • C07K 16/40 - SLLP5, sperm-specific lysozyme-like protein 5
  • C07K 16/40 - SLLP6, sperm-specific lysozyme-like protein 6
  • C07K 16/40 - YKL-40, chondrex, HCGP39, HC-gp39, human cartilage glycoprotein 39, breast regression protein 39, Brp39
Glossary of terms
In this group, the following terms (or expressions) are used with the meaning indicated:

Valency

Number of bonds formed between the antigen-binding molecule (e.g. an antibody or fragment thereof) and the target antigen

dAb, sdAb

Single domain antibody

VHH, Nanobody®

Single domain antibody derived from camelids, e.g. camels, llamas, dromedaries, characterized by an extended CDR3 loop.

VNAR

Single domain antibody derived from cartilageous fishes, e.g. sharks, rays

Synonyms and Keywords

In patent documents the following abbreviations are often used:

Ig

Immunoglobulin

Ab

Antibody

mAb, moAb

Monoclonal antibody

Carrier-bound or immobilised peptides (carrier-bound or immobilised enzymes C12N 11/00); Preparation thereof
Definition statement
This group covers:

Peptides of any size, i.e. including proteins, that are immobilised or bound to a carrier, and processes for the immobilisation or for the binding of peptides to carriers.

Relationship between large subject matter areas

Immobilised or carrier-bound peptides being part of a functional device, are usually classified according to (the purpose of) the device, e.g. A61M 1/00 for plasmapheresis, B01J 20/00 for affinity chromatography and general sorbent materials.

Immobilized or carrier-bound enzymes or microbial cells

Libraries of peptides

Screening of peptide libraries presented on the surface of microorganisms

Analytical reagents/devices comprising immobilised or carrier-bound peptides, as well as methods involving the same

Use of immobilized peptides as stationary phases in affinity chromatography for the preparation of (other) peptides

Peptides conjugated to carrier moieties in the context of the delivery of therapeutic agents

Peptides conjugated to carrier moieties in the context of the delivery of diagnostic agents

References relevant to classification in this group
This group does not cover:
  • Immobilised or carrier-bound peptides that are enzymes or are part of microbial cells,
  • - Processes and methods wherein the immobilised or carrier-bound peptides are used;
  • - Processes for the immobilisation or for the binding of peptides to carriers, wherein said processes are specific for a peptide or a certain group of peptides. In these cases, the classification follows the specific peptide(s).
Special rules of classification within this group

Particular attention is given to the nature of the solid support or the carrier and/or to the interaction of the peptide with it.

When the immobilised or carrier-bound peptides is part of a functional device, and no special interaction of the peptide with the solid support or the carrier makes a contributions over the state of the art, no class within C07K 17/00 is assigned.

The last place rule is applicable to each different embodiment disclosed, if more than one is present.

Glossary of terms
In this group, the following terms (or expressions) are used with the meaning indicated:

Peptides

compounds containing at least two amino acid units, which are bound through at least one normal peptide link, including oligopeptides, polypeptides and proteins.

Amino acids

compounds in which at least one amino group and at least one carboxyl group are bound to the same carbon skeleton and the nitrogen atom of the amino group may form part of a ring.

Normal peptide link

one between an alpha-amino group of an amino acid and the alpha-carboxy group of another alpha-amino acid.

Hybrid peptides
Definition statement
This group covers:

Hybrid peptides characterised by their non-peptide moiety, e.g. a nucleic acid; non-covaletly bound complexes of two (or more) different peptides.

Relationship between large subject matter areas

Preparations for medical, dental, or toilet purposes are classified in A61K.

References relevant to classification in this group
This group does not cover:

Fusion proteins, PEGylated proteins

Fusion proteins of an immunoglobulin with a peptide not being an immunoglobulin

General processes for the preparation of hybrid peptides

Genetic engineering processes for obtaining hybrid peptides

Preparation of hybrid peptides and proteins by fermentation or enzyme-using processes

Informative references
Attention is drawn to the following places, which may be of interest for search:

Peptides in foodstuffs

A23

Macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific, but for a random sequence of the amino acid units, homopolyamides and block copolyamids derived from amino acids

Macromolecular products derived from proteins

Preparation of glue or gelatine

Micro-organisms

Compositions for measuring or testing processes involving enzymes

Investigation or analysis of biological material

This page is owned by Office of Patent Classification.
Last Modified: 10/11/2013